# Journal of Medicinal Chemistry

# Article

Subscriber access provided by Imperial College London | Library

# Inhibitory Kappa B kinse # (IKK#) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers

Nahoum G. Anthony, Jessica Baiget, Giacomo Berretta, Marie Boyd, David Breen, Joanne Edwards, Carly Gamble, Alexander I. Gray, Alan L. Harvey, Sophia Hatziieremia, Ka Ho Ho, Judith K Huggan, Stuart Lang, Sabin Llona-Minguez, Jia Lin Luo, Kathryn McIntosh, Andrew Paul, Robin J Plevin, Murray N. Robertson, Rebecca Scott, Colin J. Suckling, Oliver Brook Sutcliffe, Louise C. Young, and Simon Paul Mackay

J. Med. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.jmedchem.7b00484 • Publication Date (Web): 24 Jul 2017

Downloaded from http://pubs.acs.org on July 24, 2017

# **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Journal of Medicinal Chemistry is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties. Young, Louise; University of Strathclyde

SCHOLARONE<sup>™</sup> Manuscripts

Mackay, Simon; University of Strathclyde, Strathclyde Institute of Pharmacy and Biomedical Science

1	
2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	

# Inhibitory Kappa B kinase α (IKKα) inhibitors that recapitulate their selectivity in cells against isoform-related biomarkers

Nahoum G. Anthony<sup>†</sup>, Jessica Baiget<sup>†</sup>, Giacomo Berretta<sup>†</sup>, Marie Boyd<sup>†</sup>, David Breen<sup>¥</sup>, Joanne Edwards<sup>§</sup>, Carly Gamble<sup>†</sup>, Alexander I. Gray<sup>†</sup>, Alan L. Harvey<sup>†</sup>, Sophia Hatziieremia<sup>†</sup>, Ka Ho Ho<sup>†</sup>, Judith K. Huggan<sup>†</sup>, Stuart Lang<sup>¥</sup>, Sabin Llona-Minguez<sup>†</sup>, Jia Lin Luo<sup>†</sup>, Kathryn McIntosh<sup>†</sup>, Andrew Paul<sup>†</sup>, Robin J. Plevin<sup>†</sup>, Murray N. Robertson<sup>†</sup>, Rebecca Scott<sup>†</sup>, Colin J. Suckling<sup>¥</sup>, Oliver B. Sutcliffe<sup>†</sup>, Louise C. Young<sup>†</sup> and Simon P. Mackay<sup>†</sup>\*

<sup>+</sup> Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0NR, Scotland, United Kingdom

\* WestCHEM Department of Pure and Applied Chemistry, University of Strathclyde, 295 Cathedral Street, Glasgow G1
 1XL, Scotland, United Kingdom

<sup>§</sup> Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Garscube Estate, Switchback Road, Glasgow, G61 1QH, Scotland, United Kingdom

#### <u>Abstract</u>

IKK $\beta$  plays a central role in the canonical NF-kB pathway, which has been extensively characterised. The role of IKK $\alpha$  in the non-canonical NF-kB pathway, and indeed in the canonical pathway as a complex with IKK $\beta$ , is less well understood. One major reason for this is the absence of chemical tools designed as selective inhibitors for IKK $\alpha$  over IKK $\beta$ . Herein, we report for the first time a series of novel, potent and selective inhibitors of IKK $\alpha$ . We demonstrate effective target engagement and selectivity with IKK $\alpha$  in U2OS cells through inhibition of IKK $\alpha$ -driven p100 phosphorylation in the non-canonical NF-kB pathway without affecting IKK $\beta$ -dependent IKappa-B $\alpha$  loss in the canonical pathway.

These compounds represent the first chemical tools that can be used to further characterise the role of IKK $\alpha$  in cellular signalling, to dissect this from IKK $\beta$  and validate it in its own right as a target in inflammatory diseases.

# **Journal of Medicinal Chemistry**

# **Introduction**

Nuclear Factor- $\kappa$ B (NF- $\kappa$ B) transcription factors are central coordinators of the innate and adaptive immune response and play key roles in cancer development and progression.<sup>1, 2</sup> NF- $\kappa$ Bs also have a major role in controlling the ability of both pre-neoplastic and malignant cells to resist apoptosis and support tumour angiogenesis and invasiveness.<sup>1, 2</sup> The signalling pathways that mediate the activation of the different NF- $\kappa$ B complexes are therefore attractive targets for new chemotherapeutic interventions.

The NF-kB pathways, which are regulated by the inhibitory kB kinases (IKKs), are elevated when homeostasis is disrupted. This is represented by an increase in constitutive IKK $\alpha/\beta$  activity leading to enhanced NF-kB expression and subsequent nuclear localisation. The IKKs are upstream regulators of the NF- $\kappa$ Bs, which exist as either homo- or heterodimers bound to inhibitory kappa Bs (I $\kappa$ B's).<sup>1, 2</sup> The activation of these IKK complexes dictates the phosphorylation, targeted ubiquitination, and proteolytic removal of IkBs in the canonical pathway and the phosphorylation and processing of high molecular weight NF- $\kappa$ B proteins (p100) in the non-canonical pathway.<sup>1, 2</sup> This in turn allows NF- $\kappa$ B complexes to translocate to the nucleus and bind specific promoter regions of their targeted genes. Studies<sup>3, 4</sup> have indicated that IKK $\alpha$  and IKK $\beta$  play key but divergent roles in the regulation of global NF-kB signalling and many aspects of cellular transcription. IKKB controls the canonical pathway via activation of p65 RelA-p50 heterodimers<sup>5-7</sup> and its inhibition leads to a reduction in pro-inflammatory gene expression in several cell types. This is relevant to cancer because several pro-inflammatory species associated with tumour development and progression are encoded by genes regulated through the IKK $\beta$ -NF- $\kappa$ B axis.<sup>3, 4, 6</sup> IKK $\alpha$  has been shown to have a minor role in the canonical pathway.<sup>4, 6</sup> but is pivotal in the non-canonical pathway, catalysing the phosphorylation and proteolytic processing of p100 NF-κB2 which in turn liberates distinct NF-κB p52/RelB dimers and initiates transcription of a specific subset of genes. IKK $\alpha$  and IKK $\beta$  have specific cellular functions<sup>3, 8, 9</sup> and the selective inhibition of one isoform over the other may provide a useful and novel therapeutic strategy in cancer and inflammatory diseases.

#### Journal of Medicinal Chemistry

Over the past 10 years, many inhibitors of IKK $\beta$  have been reported,<sup>10-13</sup> primarily towards developing clinical agents to treat inflammatory conditions such as asthma. However, recent studies suggest there may be significant toxicity and side effects associated with IKK $\beta$  inhibition, including the development of inflammatory skin disease and sensitisation of colonic epithelium to a range of insults.<sup>14</sup> In addition, IKK $\beta$  knockout mice display severe liver dysfunction.<sup>15</sup> Intestinal and liver toxicity have also been an issue in several clinical trials of IKK $\beta$  inhibitors which may further limit their clinical applications. Some IKK $\alpha$  inhibitors have been described in the patent literature, but with little detail regarding activity and specificity.<sup>16</sup> Asamitsu *et al.*<sup>17</sup> reported that the natural product, noraristeromycin (NAM), inhibits IkB $\alpha$  phosphorylation and degradation upon TNF $\alpha$  stimulation and prevents p65 phosphorylation through selective IKK $\alpha$  inhibition. However, the pharmacodynamic readouts used were reporters for both IKK $\beta$  and IKK $\alpha$  activity in cells, and do not focus on specific biomarkers of the IKK $\alpha$ -controlled non-canonical pathway, such as p100 phosphorylation and subsequent processing to p52.

Given the growing evidence that IKK $\alpha$  has an important role in a number of cancers,<sup>18-20</sup> selective IKK $\alpha$  inhibitors are required in order to fully understand and validate its role in cancer development and progression, particularly in prostate,<sup>19, 21</sup> breast<sup>22-24</sup> and pancreatic<sup>25-27</sup> cancers. Herein we describe the design, synthesis and evaluation of a series of 4-substituted 2-amino-5-cyanopyrrolo[2,3*d*]pyrimidines as part of our programme to develop isoform selective IKK $\alpha$  inhibitors. We present a comparison of the kinase domains of IKK $\alpha$  and IKK $\beta$  based on molecular dynamics simulations to explore differences in conformational flexibility that would enable small molecule inhibitors to discriminate between the two isoforms. Finally, we report the first example of IKK $\alpha$ -selective compounds that recapitulate activity in cells against isoform-related pharmacodynamic readouts.

### **Results and Discussion**

# Strategy for discriminating between IKKa and IKKβ

To date, no group has been able to successfully crystallise IKK $\alpha$  and report a high resolution structure of sufficient detail to guide structure-based inhibitor design. In order to explore differences between

#### Journal of Medicinal Chemistry

the two IKK isoforms, we built a homology model of the IKK $\alpha$  kinase domain based on the crystal structure of IKK $\beta$  (chain B, residues 1-309, PDB entry 4KIK).<sup>28</sup> keeping the inhibitor (KSA700 in the pdb file) and water molecules found within 6 Å of the protein-inhibitor complex (**Figure 1**). Both IKK kinase domains were solvated and then subjected to extended molecular dynamics, with an average structure generated for the last 21 ns (IKK $\alpha$ ) or 26 ns (IKK $\beta$ ), and subsequently minimised. When superimposing the pre-simulated structures of both IKK isoforms, it was striking to see that regions making up the ATP-binding pocket were essentially identical (**Figure 2; Left**). However, analysis of descriptors of motion extracted from their MD trajectories such as residual fluctuation revealed dynamic differences between the two isoforms that could potentially be exploited in an inhibitor design programme.

Residual fluctuations obtained from the MD trajectories highlighted areas of the IKKs that acted differently during the simulations (Figure 2; Right). Overall, the two isoforms behaved very similarly but IKK $\alpha$  appeared more flexible in several key areas around the ATP binding site, particularly at the G-loop (residues 22-27) above the site entrance and the loop located just adjacent to the hinge (residues 155-159 in IKKa (VGGKI) and residues 156-160 in IKKB (GEQRL)). Two residues could account for the differences observed with the G-loop: Pro52 and Gln48 in IKK<sup>β</sup> (Thr52 and Leu48 in IKK $\alpha$ ) induce a tension at the tip of the first  $\alpha$ -helix through proline's intrinsic structure and the engagement of the glutamine side chain in a reciprocal H-bond dimer arrangement with the side chain amide of Asn28 (Figure 3). This asparagine is located at the end of the G-loop and its interaction with Gln48 restrained the G-loop movement by more than 1 Å in IKK $\beta$  when compared with IKK $\alpha$ . A different dynamic behaviour was observed with IKK $\alpha$ , as the equivalent residues do not impose restraints on the G-loop movements: Thr52 has no rigid turn restriction like Pro52 in IKK $\beta$  and the side chain of Leu48 seeks a hydrophobic environment and will not engage in H-bond formation with Asn28, leaving the side chain of this latter residue free to make interactions in the ATP binding site of IKK $\alpha$  (in contrast to being sequestered by Gln48 as in IKK $\beta$ ) (Figure 3). The other significant difference was related to the VGGKI loop (residues 155-159) in IKK $\alpha$  (residues GEQRL: 156-160 in IKK $\beta$ ). In this case, one residue is responsible for the change observed in residual fluctuation: Lys158

in IKK $\alpha$  is replaced by Arg159 in IKK $\beta$ . The slightly longer arginine side chain and its bifurcate Hbonding capacity forms a reciprocal H-bond dimer with the side chain carboxylate of Asp128 in IKK $\beta$ that was maintained throughout the simulation, whilst the equivalent lysine in IKK $\alpha$  never engaged in a strong interaction with the equivalent Asp127 in IKK $\alpha$  (**Figure 4**). This interaction in IKK $\beta$  is responsible for tethering the 156-160 loop to  $\alpha$ -helix 3 (Asp128 is located in the middle of this helix), thus reducing its flexibility compared with IKK $\alpha$ .

With respect to putative inhibitor binding, the implications for isoform selectivity of these two sets of differences in the ATP site are two-fold: firstly, it should be possible to design small molecules that target the free Asn28 side chain amide presented at the back of the IKK $\alpha$  pocket that is otherwise engaged in IKK $\beta$  (Figure 3); and secondly, because the ATP binding pocket has greater flexibility in IKK $\alpha$ , it has the potential to accommodate larger substituents, particularly below the G-loop.



**Figure 1**. Sequence alignment for the kinase domains of IKK $\alpha$  and IKK $\beta$  (4KIK\_chainB) showing 61 % of identical residues (coloured in turquoise), a further 14 % similar residues (polar for polar, hydrophobic for hydrophobic; in light blue) and 25 % non-similar residues (white).





**Figure 2 Left**: Minimized average structure of IKK $\beta$  highlighting residues that are identical to (turquoise), similar to (light blue) or different from (white) IKK $\alpha$ . The ATP analogue marks the ATP binding site and is surrounded turquoise residues. **Right:** Residual fluctuations of IKK $\alpha$  (black line) and IKK $\beta$  (blue line) arising during the MD simulations. Several areas were found to be more flexible in IKK $\alpha$  (red underline).



**Figure 3**. Superimposition of IKK $\alpha$  (white) and IKK $\beta$  (blue) highlighting the differences near/in the ATP binding site (marked by the staurosporine analogue as a stick model) between the two isoforms. The expanded area shows equivalent residues in IKK $\alpha$  (Asn28, Leu48 and Thr52) and IKK $\beta$  (Asn28, Gln48 and Pro52) engaged in different interactions/structural effects resulting in Asn28 being available to interact with putative ligands in the binding pocket of IKK $\alpha$  but not IKK $\beta$ .



**Figure 4. Left:** Loop conformation located below the active site in IKK $\alpha$  (white) and IKK $\beta$  (blue) and its relationship with  $\alpha$ -helix 3 residue Asp127 (IKK $\alpha$ )/Asp128 (IKK $\beta$ ). In IKK $\beta$ , Arg159 makes a reciprocal hydrogen bond dimer interaction with Asp128, whereas in IKK $\alpha$  Lys158 has no close interactions with Asp127. **Right:** Side chain amine nitrogen (Lys158 (IKK $\alpha$ )/Arg159 (IKK $\beta$ )) to side chain acid oxygen (Asp127 (IKK $\alpha$ )/Asp128 (IKK $\alpha$ )/Asp128 (IKK $\beta$ )) distance throughout the equilibrated phase of the simulation.

# Initial hit identification

In order to identify hits that could be developed to exploit the differences between the two isoforms, we screened our in-house compound library compiled of fragments designed to target the common hinge-binding motif found in protein kinases. Using a DELFIA kinase assay kit with minor modifications<sup>29</sup> to measure IKK $\alpha$  and IKK $\beta$  inhibitory activity, we identified 2-amino-4-chloro-5-cyanopyrrolo[2,3-*d*]pyrimidine **4** as our primary hit (**Table 1**). Based on the assumption that the 2-aminopyrrolo[2,3-*d*]pyrimidine core of compound **4** was binding at the hinge of IKK $\alpha$ , we varied substitution at the 4-position widely. Differences in bulk and polar functionality were incorporated to exploit the greater flexibility in the IKK $\alpha$  ATP binding site and the position of the Asn28 side chain at the back of the pocket.

# Chemistry

The general route used to prepare  $N^4$ -substituted 2-amino-5-cyanopyrrolo[2,3-*d*]pyrimidines for assessment began with the preparation of 1 using a published procedure.<sup>30</sup> 1 was then protected as either its diacetyl derivative 2 or pivaloyl derivative 3, which were subsequently converted to the aryl chlorides 4 and 5 (Scheme 1) and used to prepare an initial series of compounds (4-31) (Table 1) by nucleophilic aromatic substitution with a range of primary and secondary amines. The second series of aryl cross coupled compounds exploring the 4-phenyl 2-amino-5-cyanopyrrolo[2,3-*d*]pyrimidines was prepared by Suzuki-Miyaura couplings (43-62) with 5. In general, the use of the *N*-pivalamide 5 gave higher yields of the final compounds compared to the unprotected form 4.



Scheme 1. Reagents and conditions: (a)  $Ac_2O$ , DMF, 150 °C, 4 h, ; (b) PivCl, pyridine, 85 °C, (c) POCl<sub>3</sub>, DMA, (d) Amine, Et<sub>3</sub>N, 1,4-dioxane 200 °C ( $\mu$ W) 20 mins, (e) Amine, Et<sub>3</sub>N, *n*-BuOH, reflux, 16 h then KOH, EtOH, 80 °C, 20 h, (f) boronic acid /ester, Pd(dppf)Cl<sub>2</sub>, KOAc, H<sub>2</sub>O/dioxane, 110 °C 16 h.

In order to explore polar functionality further in the  $N^4$ -substituted 2-amino-5-cyanopyrrolo[2,3d]pyrimidines, a series of amino alcohol derivatives (23-31) was prepared as analogues of 16. Compounds 23-29 were prepared from commercially available amines using the procedure detailed in Scheme 1. To incorporate 4-substituents with more than one hydroxyl group in the cyclopentane ring as in the putative IKK $\alpha$  selective inhibitor NAM, <sup>17</sup> we prepared the diol 30 and triol 31. <sup>31</sup> The 

synthesis of **30** began with bromination<sup>32</sup> of cyclopentene **32** to produce the unstable halide **33**, which was immediately treated with *N*,*N*-dibenzylamine. The resulting allylic amine **34** underwent *syn*-dihydroxylation to afford the diol **35**<sup>33</sup> with excellent diastereoselectivity, which was then protected as the dibenzoate **36**. The amine was subsequently deprotected by hydrogenation to yield **37**, which was coupled with **5**. Global deprotection gave the desired final product **30** (Scheme 2).

**Table 1**: Biochemical inhibitory data for the  $N^4$ -substituted 2-amino-5-cyanopyrrolo[2,3-*d*]pyrimidines.  $K_i$  values are expressed in  $\mu$ M units and are the result of three independent experiments.

Compound No.	R	ΙΚΚα ( <i>K</i> <sub>i</sub> ± SEM μM)	ΙΚΚβ ( <i>K</i> <sub>i</sub> ± SEM μM)	
4	CI	4.0 ± 0.9	>30	
6	NH <sub>2</sub>	>30	>30	
7	H₃C <sub>NH</sub> ∣	13.0 ± 0.51	>30	
8		16.0 ± 1.1	>30	
9	NH	1.8 ± 0.31	>30	
10	N_CH <sub>3</sub>	>30	>30	
11	NH	13 ± 1.1	>30	
12	H <sub>2</sub> N NH	>30	>30	
13	H <sub>2</sub> N <sub>S</sub> O NH	10 ± 2.9	>30	
14	NH 	5.3 ± 1.6	>30	

**ACS Paragon Plus Environment** 

15	O N N H	>30	>30
16	HO	$1.6 \pm 0.48$	>30
17		5.3 ± 0.9	>30
18	NH <sub>2</sub> O=S=O	5.3 ± 0.94	5.9 ± 0.34
19		>30	$20.0 \pm 1.3$
20	CH <sub>3</sub>	>30	>30
21	Pr-ZZ-	>30	>30
22	P P	>30	>30
23	HO	12.1 ± 6.3	>30
24	OH N	>30	>30
25		$6.0 \pm 1.6$	>30
26	HO	2.5 ± 0.14	>30
27	HO	3.1 ± 0.6	>30





Scheme 2. Reagents and conditions: (a) NBS, (PhCO<sub>2</sub>)<sub>2</sub>, CCl<sub>4</sub>, 90 °C, 1h; (b) NH(Bn)<sub>2</sub>, CCl<sub>4</sub>, rt, 12 h, 70%; (c) OsO<sub>4</sub>, NMO, acetone / H<sub>2</sub>O, rt, 4 h, 71%, 96:4 dr; (d) BzCl, pyridine, 0 °C to rt, 24 h, 84%; (e) H<sub>2</sub> (1 atm), Pd(OH)<sub>2</sub>, rt, 16 h, 98% (f) 5, Et<sub>3</sub>N, *n*-BuOH, reflux, 16 h then KOH, EtOH 80 °C, 20 h, 42%.

To prepare the triol **31**, the allyl acetate **38** was reacted with sodium di-*ter*t-butyl iminodicarbonate <sup>34</sup>, <sup>35</sup> to produce **39**, which was oxidised to the *syn*-diol **40** followed by benzoate protection of the hydroxyl functionalities to give 41, and removal of the BOC groups under acidic conditions to yield the amine 42. This was then coupled with 5 followed by basic hydrolysis to remove the protecting groups to give the desired final product **31** (Scheme 3).

An obvious progression from this series was to replace the bulky saturated ring with a phenyl ring bearing a selection of polar o-, m- or p-substituents. This series was prepared by reacting 5 with a

variety of boronic acids or esters under Suzuki-Miyaura coupling conditions to afford the products 43-

(Scheme 1; Table 2).



Scheme 3. Reagents and conditions: (a) Pd(PPh<sub>3</sub>)<sub>4</sub>, PPh<sub>3</sub>, NaH, NH(BOC)<sub>2</sub>, THF / DMF, 50 °C 24 h, 42%; (b) OsO<sub>4</sub>, NMO, acetone / H<sub>2</sub>O, rt, 24 h, 89%; (c) BzCl, pyridine, 0 °C to rt, 17 h, 74%; (d) 4N HCl in 1,4-dioxane, 0 °C to r.t, 16 h, 76%; (e) 7, Et<sub>3</sub>N, nBuOH, reflux, 16 h then KOH, EtOH 80 °C, 20 h, 33%.

**Table 2**: Biochemical inhibitory data for the 4-phenyl 2-amino-5-cyanopyrrolo[2,3-*d*]pyrimidine series.  $K_i$  values are expressed in  $\mu$ M units and are the result of three independent experiments.

$\begin{array}{c} R \stackrel{h}{\amalg} \\ N \\ H_2 N \\ H \\$				
Compound No.	R	ΙΚΚα ( <i>K</i> <sub>i</sub> ± SEM μM)	ΙΚΚβ ( <i>K</i> <sub>i</sub> ± SEM μM)	
43	H-	1.7 ± 0.95	>30	
44	4-HO-	1.6 ± 0.35	20 ± 1.2	
45	4-F-	10 ± 1.0	>30	
46	4-H <sub>2</sub> NCO-	16 ± 1.1	>30	
47	4-HOCH <sub>2</sub> -	0.65 ± 0.06	2.3 ± 1.1	
48	4-H <sub>2</sub> NSO <sub>2</sub> -	0.08 ± 0.07	1.0 ± 0.28	
49	4-CH <sub>3</sub> SO <sub>2</sub> -	2.4 ± 0.24	0.3 ± 0.6	
50	4-CH <sub>3</sub> NHSO <sub>2</sub> -	1.7 ± 1.2	$0.4 \pm 0.48$	
51	4-ToluyINHSO <sub>2</sub> -	16 ± 5.8	$1.4 \pm 0.9$	
52	4- CH <sub>3</sub> SO <sub>2</sub> NH-	1.4 ± 0.2	0.1±0.6	

53	3-HO-	2.4 ± 0.2	3.8 ± 1.7
54	3-F-	7.7 ± 1.3	>30
55	3-H <sub>2</sub> NCO-	>30	>30
56	3-HOCH <sub>2</sub> -	9.8 ± 0.54	4.0 ± 1.7
57	3- H <sub>2</sub> NSO <sub>2</sub> -	5.3 ± 0.95	5.9 ± 3.4
58	2-HO-	15 ± 1.11	>30
59	2-F-	2.0 ± 0.5	>30
60	2-H <sub>2</sub> NCO-	>30	>30
61	2-HOCH <sub>2</sub> -	>30	>30
62	2-H <sub>2</sub> NSO <sub>2</sub> -	>30	>30

In order to assess the importance of the 2-amino and 5-cyano groups for activity and selectivity, we purchased (63) or prepared compounds (64-71) without either or both substituents (Scheme 4, Table 3).



**Scheme 4.** Reagents and conditions: (a) Alkylamine, Et<sub>3</sub>N, 1,4-dioxane 200 °C (μW) 20 mins, (b) boronic acid /ester, Pd(dppf)Cl<sub>2</sub>, KOAc, H<sub>2</sub>O / dioxane, 110 °C, 16 h.

**Table 3:** Biochemical inhibitory data for the 4-substituted pyrrolo[2,3-*d*]pyrimidines with and without the 2amino and/or 5-cyano groups.  $K_i$  values are expressed in  $\mu$ M units and are the result of three independent experiments.

			$ \begin{array}{c} R_3 \\ R_1 $	2	
Compound No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	ΙΚΚα ( <i>K</i> i ± SEM μM)	ΙΚΚβ ( <i>K</i> <sub>i</sub> ± SEM μM)
4	H <sub>2</sub> N	CN /	CI	4.0 ± 0.9	>30
63	H <sub>2</sub> N	H /	CI 	>30	>30

ACS Paragon Plus Environment

48	H <sub>2</sub> N	CN /	NH <sub>2</sub> O=S=O	0.08 ± 0.07	1.0 ± 0.28
64	H <sub>2</sub> N	H /		2.9 ± 0.71	0.61 ± 0.23
65	н	H /	NH2 O=S=O	1.5 ± 0.36	2.5 ± 1.1
66	н	CN /	NH <sub>2</sub> O=S=O	2.1 ± 0.5	>30
67	H <sub>2</sub> N	H /	<b></b>	>30	>30
68	H <sub>2</sub> N	H /	ZH-	>30	>30
69	H <sub>2</sub> N	H /	HO	>30	>30
70	H <sub>2</sub> N	CF <sub>3</sub> /	NH -	>30	>30
71	H <sub>2</sub> N	O NH <sub>2</sub>	HO	>30	>30

Structure-activity relationship studies

In the  $N^4$ -substituted series (**Table 1**) several compounds had similar  $K_i$  values against IKK $\alpha$  compared to the initial hit **4**. For example, compounds with aliphatic substituents retained potency and selectivity against IKK $\alpha$  and had the potential to be improved through further derivatisation. Inhibitory activity for the secondary amines (**7**, **8**, and **9**) suggests the presence of a restricted lipophilic pocket in IKK $\alpha$ , which could be responsible for a five-fold increase in potency from the methylamine analogue **7** to the cyclohexylamine derivative **9**. However, the inactivity of the

compound with the bulkier cyclohexylmethylamino group (10) suggested that this lipophilic pocket was limited in size. In contrast, the more planar phenyl and benzyl analogues (11 and 14) were found to be less active than 9, and the insertion of polar substituents in the *para* position of the aniline group produced no significant improvement in activity (12 and 13). Conversely, the insertion of polar groups in more flexible side chains was tolerated (16), which suggested the presence of a polar region adjacent to the lipophilic pocket.

Although compounds with a piperidyl side chain (17 and 18) were found to be active, other tertiary amines at position 4 were not tolerated (19-22), which could be due to additional heteroatoms not being accepted in a lipophilic area of the binding directly proximal to position 4 of the pyrrolo[2,3-d]pyrimidine scaffold. By contrast, the activity of 16 suggested that a flexible ethyl chain is able to direct the heteroatom away from this lipophilic region, and possibly engage an adjacent polar region more effectively.

Removal of the hydrogen bond donor (HBD) from the 4-amino substituent by replacing the secondary cyclohexylamino group in **9** with the tertiary *N*-methylcyclohexylamine (**10**) abrogated activity. However the activity of piperidyl analogue **17** suggests that a HBD at the 4-position is not an absolute requirement for inhibition of IKK $\alpha$ . The inactivity of compound **10** can be explained by rotation of the *N*-methyl (and hence the cyclohexyl group) substituent orthogonal to the pyrrolo[2,3-d]pyrimidine moiety to reduce steric clash with the 5-cyano substituent and generate a conformation that is no longer compatible with the binding site.

Based on the activity of the 4-hydroxyethylamino derivative **16**, we prepared a second series of amino alcohol derivatives (**Table 1**). Extending the alkyl chain of **16** from ethyl to propyl was detrimental to activity (**23**), whereas the cyclic analogues produced more interesting results. The (*R*)-pyrrolidin-3-ol enantiomer **25** was active and selective against IKK $\alpha$  whereas the (*S*)-enantiomer **24** was inactive, suggesting the directionality of the hydroxyl group had a major influence on activity and selectivity. On the other hand, the (*R*)- and (*S*)-pyrrolidin-2-yl methanol enantiomers **26** and **27** shared the same activity and selectivity against IKK $\alpha$  implying that free rotation around the methyl alcohol is sufficient to allow equivalent interactions.

#### Journal of Medicinal Chemistry

The *trans*-aminocyclohexanol derivative **28** was also active and selective against IKK $\alpha$ , but the cyclohexylamino ethyl alcohol **29**, designed as a hybrid of compounds **8** and **16**, proved to be inactive. Like compound **10**, this is probably due to the aliphatic ring and the ethyl chain being twisted 90° away from the nitrile axis to adopt a more energetically favoured conformation that is incompatible with the binding site. The diol **30** was active and selective, but did not offer significant improvement. The triol **31**, prepared as an analogue of NAM, proved to be as active as **30** but less selective. Overall, no significant improvement in binding or selectivity was gained by the introduction of more than one hydroxyl group in this series of secondary cyclic amine derivatives.

The direct attachment of an aromatic ring to position 4 of the pyrrolo[2,3-*d*]pyrimidine scaffold exemplified by compound 43 retained the potency and selectivity of the original hit 4 (**Table 2**). In general, compounds with *para* substituents in the phenyl ring had better activity against IKK $\alpha$  and produced our first nanomolar IKK $\alpha$  inhibitors in 47 and 48. Although activity against IKK $\beta$  was evident for these two compounds, their higher potency for IKK $\alpha$  ensured significant isoform selectivity was maintained. Compounds with *meta* substituents were low micromolar inhibitors of IKK $\alpha$  (for example 53, 56 and 57) but were equipotent against IKK $\beta$ , apart from 55, which was inactive against both isoforms. As with compounds 10 and 28, the inactivity of the *ortho*-substituted derivatives in this series can be attributed to enforced conformational rotation of the phenyl ring to a more orthogonal relationship with the pyrrolo[2,3-*d*]pyrimidine scaffold, which introduces steric clashes in the binding site. This is less pronounced with an *o*-fluoro substituent and consequently, **59** had similar potency to the unsubstituted 4-phenyl derivative **43**.

Compound **48** (proprietary code **SU909**), with a *para*-primary sulfonamide represents the most potent IKK $\alpha$  inhibitor reported to date that has significant selectivity over IKK $\beta$ , although a limited kinase profile using 40 kinases representative of the kinome identified off-target effects (>80% inhibitory activity) with other kinases (Aurora A; CaMK1; CHK2; CK1; GSK3; MEK1 and PKC: **Figure 5**).



Figure 5: % Residual activity of 40 kinases challenged with compound 48 at 10 µM.

To explore the role of the primary sulfonamide, the 4-methyl sulfone analogue **49** and the secondary sulfonamides **50** and **51** were prepared. Notably, **49** and **50** had reduced potency against IKK $\alpha$ , but both were more active against IKK $\beta$ , reversing the isoform selectivity for the first time in this series. Similarly, when the orientation of the sulfonamide with respect to the phenyl ring (**52**) was reversed, a reduction in potency against IKK $\alpha$  occurred but an improvement against IKK $\beta$  was again evident, inverting isoform selectivity.

The absence of a 5-cyano group in **48** (compound **64**) reduced activity against IKK $\alpha$  more than 30fold (**Table 3**), although there was a slight improvement against IKK $\beta$ . Compound **65**, which lacked both the 5-cyano and the 2-amino substituent had lower activity against both isoforms. Compound **66**, without the 2-amino group but with the 5-cyano, attenuated IKK $\beta$  activity but did not re-establish the potency against IKK $\alpha$  seen for **48**. The importance of the 5-cyano group for activity against IKK $\alpha$  was further demonstrated by preparing analogues of selected active  $N^4$ -substituted exemplars from **Table** 1: removal of the 5-cyano substituent produced inactive compounds against both isoforms (**67-69**), and its replacement with other electron-withdrawing substituents such as a trifluoromethyl (**70**) or a carboxamide (**71**) moiety also attenuated all IKK $\alpha$  inhibitory activity (**Scheme 4, Table 3**). Furthermore, compound **63**, which represents the original hit compound (**4**) without the 5-cyano group, was also inactive against IKK $\alpha$  (**Table 3**).

#### **Journal of Medicinal Chemistry**

Overall, our SAR data suggest that the 5-cyano substituent is essential for IKK $\alpha$  activity in this series of compounds, but must be combined with a 2-amino group to promote selectivity. To enhance potency for IKK $\alpha$ , a 4-phenyl group bearing a specific polar *para*-substituent appears to be crucial.

# Docking studies

In order to explain the general SAR profile observed with our series and to relate these to the differences between the two IKK isoforms that our MD studies had revealed, we performed docking studies using GOLD.<sup>36</sup> A limited flexibility was enabled in the side chains of specific residues that had shown significant fluctuation in the MD trajectories, namely Asn28, Val29 and Lys44. In the cocrystal structure of IKK $\beta^{28}$  that had formed the basis of our simulations, the staurosporine analogue interacts though H-bonds with the backbone groups of GK+1 (Glu97) and GK+3 (Cvs99) in the conserved hinge region. Initially, no attempt was made to direct the ligands to interact specifically with the hinge region in our docking simulations; the only requirement was to occupy the ATP binding site. This first docking study was performed to find a common binding mode that could explain the IKK $\alpha$  inhibitory activity and selectivity reported for exemplars from our two series. To explore this, compounds bearing different hydrophobic substituents were selected for their similar potency and selectivity (e.g. 4, 9 and 43). The poses where the 2-aminopyrrolo[2,3-d]pyrimidine scaffold interacted with the hinge region by H-bonds were studied in detail and compared to similar hinge-binding protein kinase inhibitors.<sup>37</sup> For example, aminopurines are known to adopt two different binding modes in interactions with the hinge region of CDK2 via three hydrogen bonds.<sup>38</sup> However in similar poses for our compounds in IKK $\alpha$ , the analogous triplet of hydrogen bonds was poorly supported by the IKK $\alpha$  hinge region in terms of bond distances and bond angles. Not surprisingly, similar poses were found when the same compounds were docked with IKK $\beta$ , which is due to the high isoform homology and subtle differences in topography in this hinge region of the ATP binding site. These poses could not account for the selectivity reported in our assays and suggested that this was not the binding mode responsible for conveying such discriminatory activity between the isoforms. However, a binding mode where the 2-aminopyrrolo[2,3-d]pyrimidine scaffold interacted with the back pocket of the IKK $\alpha$  active site explained the potency and selectivity displayed

by our compounds more effectively. Figures 6A-C illustrate how compounds 4, 9 and 43 were predicted to interact with IKK $\alpha$ , specifically targeting the carboxylate group of Glu61, the ammonium group of Lys44 and, most significantly, the side chain carbonyl group of Asn28 via four H-bonds. In IKK $\beta$ , because Asn28 is involved in a dimeric H-bond interaction with Gln48 revealed by our simulations (Figure 3), which also changes the position of Glu61, the triple H-bond interaction observed in IKK $\alpha$  is lost. We therefore propose that the aminopyrrolo[2,3-d]pyrimidine scaffold is anchored to the back of the ATP site specifically targeting Asn28 in IKK $\alpha$ , which accounts for the observed selectivity. In this orientation, the importance of the 5-cyano group when binding with IKKa can also be explained. Examination of the trajectory from an MD simulation of 47 revealed a water molecule present for the majority of the run that formed a 3-centred hydrogen bond bridge between the nitrile, the side chain carboxylate of Asp102, and the backbone NH of the same residue (Figure **6D**). Overall, binding to IKK $\alpha$  appears to be facilitated through four centres on the 2-amino-5cyanopyrrolo[2,3-d]pyrimidine scaffold with four residues in the ATP binding site: Glu61, Lys44, Asn28 and Asp102. A similar binding orientation with IKK $\beta$  is less likely because the two of the equivalent sites are less accessible (Asn28 and Glu61) and this would account for the lack of activity in this isoform.

Although the poses described for compounds 4, 9 and 43 showed no interaction with the hinge region, the equivalent poses for the nanomolar inhibitors 47 and 48 had significant H-bond interactions with the GK+3 residue via their *p*-hydroxymethyl and *p*-sulfonamide substituents (Figures 6D and 7). The equivalent binding pose in IKK $\beta$  did not feature the hydrogen bonds HB1 and HB2 due to local structural differences observed between the kinase isoforms, and could explain the lower affinity of 48 for IKK $\beta$ . Interestingly, the presence of the methyl group in the secondary sulfonamide 50 compromised its ability to form an H-bond with the HBA carbonyl group of GK+3 because of a steric clash with the hinge region, thus reducing affinity for IKK $\alpha$ . The sulfonyl group could still interact with the NH of GK+3, which explains why 50 and the sulfone 49 both have similar potency against IKK $\alpha$ .

Page 21 of 67

#### Journal of Medicinal Chemistry

The reason for both 49 and 50 also having greater inhibitory activity against IKK $\beta$  that reverses isoform selectivity is because the polar side chain of Asn28 in IKK $\beta$  rotates out of the back pocket to H-bond with Gln48 (Figure 3). When 49 and 50 were docked in the IKKß structure, they commonly adopted a flipped pose, where the 2-aminopyrrolo [2,3-d] pyrimidine engaged with the GK+1 and +3 residues at the hinge through H-bonding, whilst the sulfonyl oxygen and the 5-cyano group H-bonded with K44 in the back pocket (Figure 8). Binding to IKK $\beta$  by 49 and 50 in this orientation is facilitated by moving the polar Asn28 from the immediate vicinity creating a cleft that can more easily accommodate the hydrophobic methyl moiety of 49 and 50. A similar reversal of selectivity was seen with 64, which lacks the 5-cyano substituent of 48. The drop in potency against IKK $\alpha$  can be attributed to the absence of a water-bridging H-bond interaction with Asp102, but also to the removal of the conformationally-restraining effect of the 5-cyano group on the adjacent 4-phenyl ring which would normally optimise alignment of the *p*-sulfonamide H-bonding interaction with GK+3 in the hinge. The enhanced affinity for IKK $\beta$  by 64 can again be explained by the adoption of a flipped pose when binding to this isoform, which is enabled by a more flexible *p*-sulfonamide that can H-bond more effectively with Lys44. Just as importantly, this flexibility allows the HBD of the sulfonamide group to access the less accessible Glu41 at the back of IKK $\beta$  pocket.

In summary, in line with our SAR data and the hypothesis derived from our MD simulation studies, we suggest that nanomolar potency against IKK $\alpha$  with selectivity over IKK $\beta$  can be accomplished by having molecules that can bind to the hinge region of the ATP binding site and to the Asn28 residue at the back of the pocket that is available in IKK $\alpha$  but not in IKK $\beta$  (**Figure 8**). Furthermore, inhibitory potency against IKK $\alpha$  can be enhanced when compounds can form H-bonding interactions with the three residues in the back pocket (Glu41, Lys44, Asn28) and the GK+3 and Asp102 residues in the hinge.



**Figure 6.** Docked poses of **4**, **9**, **43** and **47** (A-D respectively) binding to the back of the ATP pocket in IKK $\alpha$ , where the 2- aminopyrrolo[2,3-*d*]pyrimidine motif forms H-bonds (shown in green) with the side chain carboxylate of Glu61, the side chain ammonium group of Lys44 and the side chain carbonyl group of Asn28. No equivalent poses were identified when these compounds were docked with IKK $\beta$ . Figure 6D shows that an MD simulation of **47** revealed an additional interaction with a molecule of water that formed an H-bond bridging interaction between the 5-cyano group, the side chain of Asp102 and the backbone NH of the same residue.



**Figure 7**. Left: docked pose of **48**. As before, the 2- aminopyrrolo[2,3-*d*]pyrimidine moiety engages with the back of the ATP pocket in IKK $\alpha$  and the sulfonamide group generates additional H-bonds with the main chain carbonyl and NH of GK+3 that produce nanomolar activity. **Right:** Schematic representation of the proposed binding mode in the IKK $\alpha$ -ATP binding site showing key interactions for compound **48**.



**Figure 8**. Left: docked pose of **50** in IKK $\beta$ . Unlike IKK $\alpha$ , the aminopyrrolo[2,3-*d*]pyrimidine moiety has flipped and H-bonds to GK+1 and GK+3. The rotation of Asn28 out of the pocket to H-bond with Glu48 allows the sulfonyl group to H-bond to Lys44 and accommodates the lipophilic methyl group in the cleft opened up by this rotation. **Right:** Schematic representation of the proposed binding mode in the IKK $\beta$ -ATP binding site showing key interactions for compound **50**.

Demonstrating IKKa activity and selectivity is recapitulated in cells.

The objective of the cell-based assessment was to characterise whether the two most active compounds, **47** and **48** against IKK $\alpha$  recapitulated their activity in a cellular environment. IKK $\alpha$  but not IKK $\beta$  plays a role in the regulation of the non-canonical NF- $\kappa$ B cascade which initially involves phosphorylation of p100, followed by p100 processing to p52 to regulate a number of genes that contribute to and promote cellular growth.<sup>39</sup> More recent studies have shown that over-activation of the non-canonical NF- $\kappa$ B pathway in a variety of cellular settings e.g. prostate,<sup>19, 21</sup> pancreas<sup>25-27</sup> is inherently associated with cell survival and proliferation. The U2OS osteosarcoma cell line is representative of these proliferative characteristics and is dependent on constitutively activated IKK $\alpha$  signalling;<sup>40</sup> it was therefore selected as the system to demonstrate perturbation of IKK $\alpha$  activity in the cellular environment.

Pre-treatment of U2OS cells with increasing concentration of **48** and **47** resulted in concentrationdependent inhibition of FCS-stimulated phosphorylation of p100 (**Figures 9a** and **10a**). The IC<sub>50</sub> values for **48** and **47** were calculated as 8.8  $\mu$ M and 13.9  $\mu$ M respectively. Two IKKβ-dependent readouts were selected to assess selectivity over IKKβ . Firstly, TNF $\alpha$  stimulates IkB $\alpha$  degradation through activation of IKK $\beta$  and if IKK $\beta$  is inhibited, then a band corresponding to the IkB $\alpha$  protein should be evident by Western analysis. Secondly, IKK $\beta$  phosphorylates p65 on Ser536, which can also be assessed by Western blot analysis. Only at the highest concentration (100  $\mu$ M) of **48** was IkB $\alpha$  degradation and p65 (Ser536) phosphorylation inhibited (**Figure 9b**). Even at this high concentration these effects were not apparent following pre-treatment with **47** (**Figure 10b**).

To provide further evidence for cellular activity, mouse embryonic fibroblasts lacking the IKK $\beta$  kinase sub-unit were utilised to investigate the potency of both compounds against agonist-stimulated IKK $\alpha$ -regulated NF- $\kappa$ B transcriptional activation. Cells were infected with an adenovirus encoding an NF- $\kappa$ B-luciferase promoter gene. NF- $\kappa$ B transcriptional activity driven by IKK $\alpha$  was stimulated specifically using IL-1 $\beta$ , <sup>41</sup> and the ability of the compounds to inhibit this response was assessed. At

#### Journal of Medicinal Chemistry

maximal concentrations of 50-100  $\mu$ M **48** abolished transcriptional activity compared to **47** which inhibited activity by approximately 81% (% stim: Il-1 $\beta$ +DMSO = 100%, **48**+Il-1 $\beta$  = -40.9 ± 4.6%, **47**+IL-1 $\beta$  = 18.79 ± 7.2%, both \*\*P<0.01). Both **47** and **48** demonstrated concentration-dependent inhibitory effects on FCS-induced phosphorylation of p100 by IKK $\alpha$ . As IKK $\alpha$  plays a lesser role in the canonical NF- $\kappa$ B cascade,<sup>42</sup> particularly the rapid and transient stimulated degradation of I $\kappa$ B $\alpha$ , selective IKK $\alpha$  inhibitors should not affect TNF- $\alpha$  induced I $\kappa$ B $\alpha$  degradation and p65 phosphorylation. Compound **47** did not affect either agonist stimulated I $\kappa$ B $\alpha$  degradation or p65 phosphorylation, whilst **48** only had a small effect on both markers at the highest concentration tested (100  $\mu$ M). Taken together, these data demonstrate that **47** and **48** are the first examples of IKK $\alpha$ selective compounds that inhibit agonist-stimulated NF- $\kappa$ B signalling of the non-canonical pathway at much lower concentrations than the canonical pathway.



**Figure 9:** The effect of compound **48** on (a) FCS-stimulated non-canonical and (b) TNF- $\alpha$ -induced canonical NF-kB activation in U2OS cells. Cells were pre-treated with **48** 1 h prior to stimulation with FCS (10%) for 4 h or TNF- $\alpha$  (10 ng/ml) for 30 min. Whole cell lysate were prepared, separated by SDS-PAGE and assessed for (a) inhibition of p100 phosphorylation (Ser866/870) and (b) IkB- $\alpha$  and p-p65 (Ser536) status. (c) Blots were quantified and the IC<sub>50</sub> value for inhibition of p100 phosphorylation was determined (**48** IC<sub>50</sub> = 5.8  $\mu$ M). The results are representative of 3 independent experiments.



**Figure 10:** The effect of compound **47** on (a) FCS-stimulated non-canonical and (b) TNF- $\alpha$ -induced canonical NF-kB activation in U2OS cells. Cells were pre-treated with **47** 1h prior to stimulation with FCS (10%) for 4 h or TNF- $\alpha$  (10ng/ml) for 30 min. Whole cell lysate were prepared, separated by SDS-PAGE and assessed for (a) inhibition of p100 phosphorylation (Ser866/870) and (b) IkB- $\alpha$  and p-p65 (Ser536) status. (c) Blots were quantified and the IC<sub>50</sub> value for inhibition of p-p100 was determined (**47** IC<sub>50</sub> = 19.1µM). The results are representative of 3 independent experiments.

**Table 4: II-1** $\beta$ -stimulated NF- $\kappa$ B transcriptional activation in IKK $\alpha^{-/-}$  MEFs. IKK $\beta^{-/-}$  MEFs infected with Adv.NF-kB.luc were grown to near confluency and rendered quiescent by serum deprivation for 24h. Cells were then pre-treated for 1 hour with increasing concentrations of compounds 48 or 47 prior to stimulation with IL-1 $\beta$  (10ng/ml) for a further 6 h. Cells were assayed for NF- $\kappa$ B-linked luciferase reporter activity, as outlined in the methods section. Values (RLUs) were collated and converted to percentage stimulation (of positive control = IL-1 $\beta$  + DMSO). Each value represents the mean  $\pm$  s.e.m from at least 4 independent experiments and data was quantified using one way ANOVA, with DUNETTS post-test.

Treatment	% stimulation
IL-1β + DMSO	100
II-1β + <b>47</b> (100 μM)	-40.9 <u>+</u> 4.6 **
II-1β + <b>48</b> (100 μM)	18.79 <u>+</u> 7.2 **

\*P < 0.05, \*\*P < 0.01 compared to IL-1 $\beta$ +DMSO alone.

#### **Journal of Medicinal Chemistry**

# **Conclusion**

There are many reported inhibitors of IKK $\beta$ , primarily because it was considered a viable target in inflammatory disease. Designing inhibitors of IKK $\alpha$  that are selective over IKK $\beta$  has to this date not been reported, despite the former isoform now being recognised as a potential target in a number of cancers. One reason for this is the high sequence-homology in the ATP-binding site of the two isoforms and the absence of any high resolution crystal structure of IKK $\alpha$  to guide structure-based inhibitor design.

By employing molecular dynamics simulations on a homology model of IKK $\alpha$  based on IKK $\beta$ , we identified key dynamic differences at the ATP-binding site and exploited these to design the first selective inhibitors of IKK $\alpha$ . Our compounds demonstrated target engagement with IKK $\alpha$ -related pharmacodynamic markers and non-engagement with IKK $\beta$  markers in cells. These compounds therefore represent the first chemical tools that can be used to further characterise the role of IKK $\alpha$  in cellular signalling, to dissect this from the very similar IKK $\beta$  isoform and validate IKK $\alpha$  in its own right as a target in cancers, such as prostate, breast and pancreatic cancer.

The discovery of a 2-aminopyrrolo[2,3-*d*]pyrimidine chemical series also provides valuable information with respect to SAR for IKK $\alpha$  inhibitory activity. Substituents at position 4 of the pyrrolo[2,3-*d*]pyrimidine scaffold allowed for diversification, with IKK $\alpha$  selectivity achievable through the introduction of groups that specifically target residues in its binding site. However, further significant improvements in activity through aliphatic 4-amino substituents appear to be unlikely. Modifying the 4-phenyl substituent offers a more promising route towards generating compounds with improved activity and selectivity. Using this strategy, we are currently developing more potent IKK $\alpha$ -inhibitors that display functional outputs in a number of cell lines, all of which will be reported in due course.

# **Experimental**

# <u>IKKα homology model</u>

Building a homology model of IKK $\alpha$ : the kinase domain of IKK $\beta$  (chain B, residues 1-309, PDB entry 4KIK <sup>28</sup> was used as a template to build the kinase domain of IKK $\alpha$ , keeping the inhibitor (KSA700 in the pdb file) and waters found within 6 Å of the protein-inhibitor complex. The residue alignment (Figure Mod1) and homology building were performed using Discovery Studio 3.1 (Accelrys Inc., San Diego, USA) after missing residues D174, Q175 and G176 were added in an extended conformation.

Both IKK kinase domains were subjected to molecular dynamics using the AMBER12 simulation software. The inhibitor present (residue name KSA700) was kept and parameterised using antechamber and charges calculated and fitted using the AM1-BCC scheme. The two systems were placed in a periodic octahedral box and solvated with TIP3P water with outer edges 6 Å in each direction from the closest solute atom. The systems were then neutralized and physiological salt conditions applied (~150 mM) by adding 24 Cl- and 29 Na+ ions to the IKK $\alpha$  system and 24 Cl- and 30 Na+ ions to the IKKB system. The AMBER ff12SB was applied to all protein atoms whilst gaff was used for the ligand. Parameters for the phosphoserine residues were taken from Craft and Legge <sup>43</sup>. Before the MD production phase, minimization and equilibration (to reach 310 K) were performed in two stages as described <sup>44</sup>. The NPT ensemble was used at 310 K until the systems had stabilized for at least 20 ns (50 and 100 ns simulation time for IKK $\beta$  and IKK $\alpha$  respectively). All MD steps used the SHAKE algorithm <sup>45</sup> with a 2 fs time-step and a 10 Å cutoff for long-range electrostatic interactions. An average structure was generated (using ptraj within the AMBER suite) for the last 21 ns (IKK $\alpha$ ) or 26 ns (IKK $\beta$ ) and subsequently minimised in three steps, with the solvent, ions, and hydrogen atoms initially minimized while the protein and inhibitor were restrained by 100 kcal mol<sup>-1</sup>  $Å^{-2}$ . The restraint was then removed from the protein side chain atoms, and finally the whole system was allowed to minimize until a derivative of 0.1 kcal mol<sup>-1</sup> Å<sup>-2</sup> was achieved. These structures were then utilized for further docking studies with the GOLD software.

# **General Experimental**

#### Journal of Medicinal Chemistry

Solvents (reagent grade or better) were purchased from Sigma-Aldrich or Fischer Scientific. Anhydrous solvents where purchased from Sigma-Aldrich. Deuterated solvents were purchased from Sigma-Aldrich. Chemicals (95% purity or above) were purchased from Acros Organics, Alfa Aesar, Apollo, Fluorochem or Sigma-Aldrich. Solvents and chemicals were used as received without further purification or treatment.

Oxygen- or moisture-sensitive reactions were carried out under a nitrogen atmosphere.

Microwave reactions were performed with a Biotage Initiator system. High absorbance was selected for polar solvents and normal absorbance was selected for non-polar solvents.

The progress of the reactions was monitored on Merck 60F254 TLC plates. Spots were visualized by irradiation with ultraviolet light (254/366 nm) or KMnO4, ninhydrin or phosphomolibdic acid (PMA) TLC stains.

Column chromatography was performed with a Biotage SP4 system; cartridge size and eluent specified in the corresponding experiments (% is referring to the most polar solvent in the mixture); using silica gel as the stationary phase (particle size 0.040-0.063 mm, Merck or Fisher Scientific).

Specific rotations were measured in a Perkin Elmer Polarimeter 341 apparatus at 20 °C and a wavelength of 589 nm (sodium D line) in DMSO UV spectrophotometric analysis grade.

1H and 13C NMR data were recorded on either a JEOL ECX-400 (400 MHz) or Bruker Avance3/DPX400 (400 MHz) spectrometers at 400.0 and 100.6 MHz respectively. Chemical shifts ( $\delta$ ) are expressed in parts per million (ppm) coupling constants (*J*) are in hertz (Hz). Chemical shifts ( $\delta$ ) are reported relative to TMS ( $\delta = 0$  ppm) and/or referenced to the solvent in which they were measured. All measurements were carried out at 298 K (except when stated). Abbreviations used in the description of NMR data are as follows: app, apparent; s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; p, pentuplet; m, multiplet.

HR-MS was conducted using a Thermo Scientific Exactive Orbitrap Mass Analyzer. LR-MS was conducted using a ThermoQuest Finnigan LCQ Duo instrument. GC-MS was conducted using a ThermoQuest Finnigan Polaris Q instrument.

Final compounds tested in the kinase inhibition assay possessed a purity of  $\geq$  95% by HPLC analysis (unless stated otherwise) conducted using an Agilent Technologies 1220 series system (Methods A, B, C and D). Column: Agilent Eclipse XDB C18 4.6 mm ID x 250 mm (5µm) 80Å. Flow rate: 1 mL / min. Detector: 254 nm. Sample volume: 10 µL. Mobile phase: **Method A**) 15% MeCN in H<sub>2</sub>O (3 min), 15 to 90% MeCN in H<sub>2</sub>O (12 min) followed by equilibration / blank run; **Method B**) 5% MeCN in H<sub>2</sub>O (3 min), 5 to 100% MeCN in H<sub>2</sub>O (14 min), 100% MeCN in H<sub>2</sub>O (5 min), 100 to 5% MeCN in H<sub>2</sub>O (5 min), 5% MeCN in H<sub>2</sub>O (5 min) followed by blank run; **Method C**) 5% MeCN + 5 mM NH<sub>4</sub>Ac in H<sub>2</sub>O + 5 mM NH<sub>4</sub>Ac (3 min), 5 to 100% MeCN + 5 mM NH<sub>4</sub>Ac (5 min), 100 to 5% MeCN in H<sub>2</sub>O (5 min), 5% MeCN + 5 mM NH<sub>4</sub>Ac in H<sub>2</sub>O + 5 mM NH<sub>4</sub>Ac (5 min) followed by blank run. **Method D** was conducted in a Dionex UltiMate 3000 LC system. Column: ACE 3 C8 3 mm ID x 50 mm. Mobile phase: 5 to 95% MeCN + 0.1% HCO<sub>2</sub>H in H<sub>2</sub>O + 0.1% HCO<sub>2</sub>H (1 min), 5% MeCN + 0.1% HCO<sub>2</sub>H in H<sub>2</sub>O + 0.1% HCO<sub>2</sub>H (5 min). Flow rate: 0.4 mL / min. Detector: 254 nm. Sample volume: 10 µL.

#### **Experimental section**

# 2-Amino-4-oxo-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 1.

Methyl formate (18.0 mL, 17.48 g, 291.4 mmol) in toluene (8 mL) was added at 0 °C to a stirred suspension of NaOMe (14.30 g, 264.9 mmol) in toluene (200 mL). This was followed by dropwise addition of chloroacetonitrile (16.8 mL, 20.00 g, 264.9 mmol) in toluene (60 mL) over 1 h. The reaction mixture was stirred for 3 h followed by addition of H<sub>2</sub>O (150 mL). The organic layer was separated and the aqueous layer was acidified to pH 5 using 6M HCl and subsequently extracted with EtOAc (3x100 mL). The organic layers were combined and dried over MgSO<sub>4</sub> and concentrated *in vacuo* (40 °C, 70 mbar). The dark residue was suspended in H<sub>2</sub>O (60 mL) and added to a solution of NaOAc (16.39 g, 199.8 mmol) and 2,6-diaminopyrimidin-4(3*H*)-one (12.00 g, 95.2 mmol) in H<sub>2</sub>O (200 mL) (previously stirred at 100 °C until complete dissolution). The reaction was refluxed for 16 h. After cooling to room temperature the suspension was filtered and washed with H<sub>2</sub>O (2x20 mL),

#### Journal of Medicinal Chemistry

acetone (2x10 mL) and Et<sub>2</sub>O (2x 40 mL) to yield **1** (10.11 g, 60%) as a light tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ: 6.37 (bs, 2H), 7.58 (s, 1H), 10.70 (bs, 1H), 11.95 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ: 86.0, 99.2, 116.3, 128.2, 158.0, 152.1, 154.2. 3

# *N*-(7-Acetyl-5-cyano-4-oxo-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidin-2- yl)acetamide 2

A suspension of **1** (1.18 g, 6.74 mmol) in acetic anhydride (18 mL) and dry DMF (10 mL) was heated at 150 °C for 4 h. Solvents were evaporated *in vacuo* and the residue was triturated with Et<sub>2</sub>O (2x10 mL) to yield **2** (1.65 g, 95%) as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.22 (s, 3H), 2.86 (s, 3H), 8.41 (s, 1H), 11.73 (bs, 1H), 12.20 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 24.5, 26.0, 90.5, 105.1, 114.2, 129.8, 148.9, 149.3, 155.7, 168.5, 174.4.

# *N*-(5-Cyano-4-oxo-4,7-dihydro-3*H*-pyrrolo[2,3-*d*]pyrimidin-2-yl)pivalamide 3

1 (7.33 g, 28.30 mmol) was stirred in dry pyridine (60 mL) at 60 °C for 1 h. Upon formation of a homogenous suspension, the mixture was cooled to 0 °C and treated dropwise with pivaloyl chloride (10.5 mL, 10.23 g, 84.87 mmol). The suspension was then stirred at 85 °C for 2 h. After cooling to room temperature, the resulting suspension was neutralized with 33% ammonia in H<sub>2</sub>O and left to stand at 4 °C for 16 h. The suspension was filtered off, washed with H<sub>2</sub>O (10 mL), dried and then triturated with Et<sub>2</sub>O (2x10 mL) to afford **3** (6.97 g, 64%) as a pale brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.25 (s, 9H), 7.93 (s, 1H), 11.00 (bs, 1H), 12.11 (bs, 1H) and 12.65 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 27.0, 40.7, 86.9, 103.7, 115.9, 130.9, 149.1, 149.1, 156.4, 181.7.

# 2-Amino-4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 4

POCl3 (5.2 mL, 8.57 g, 55.9 mmol) was added dropwise to a suspension of **2** (1.61 g, 6.21 mmol) and *N*,*N*-dimethylaniline (1.2 mL, 1.13 g, 9.32 mmol) in dry MeCN (10 mL). The reaction mixture was heated at 100 °C for 6 h. After cooling to room temperature, the mixture was placed in an ice bath and neutralized with saturated aqueous Na<sub>2</sub>CO<sub>3</sub>. The suspension was filtered off, washed with H<sub>2</sub>O (10 mL), dried and then triturated with Et<sub>2</sub>O (2x10 mL) to afford **6** (1.44 g) as a brown solid. Chromatographic purification (Manual column, solvent system: MeOH/EtOAc, gradient: 0% 50 mL;

0-25% 200 mL; 25% 100 mL) yielded a pure analytical sample of **6**. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 6.95 (bs, 2H), 8.11 (s, 1H), 12.52 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 83.5, 106.5, 115.4, 134.5, 151.5, 155.0, 160.8; HRMS (ESI) calculated for for C<sub>7</sub>H<sub>5</sub>N<sub>5</sub>Cl [M<sup>+</sup>H]<sup>+</sup> 194.0228, found 194.0229; HPLC *t*R = 5.56 min (Method D).

# N-(4-Chloro-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-2-yl)pivalamide 5

A suspension of **3** (6.82 g, 26.31 mmol), *N*,*N*-dimethylaniline (14 mL, 13.39 g, 110.48 mmol) and triethylbenzylammonium chloride (2.93 g, 13.15 mmol) in dry MeCN (100 mL) was treated dropwise with POCl<sub>3</sub> (24.5 mL, 40.33 g, 263.05 mmol). The reaction mixture was refluxed for 1 h, allowed to cool down and concentrated *in vacuo*. The resulting dark oil was cautiously treated with ice and was set to pH = 5 using 33% ammonia in H<sub>2</sub>O. The aqueous layer was extracted with EtOAc (4x100 mL) and the combined organic layers were dried over MgSO<sub>4</sub> and concentrated *in vacuo*. The residue was triturated with Et<sub>2</sub>O (3x30 mL), MeOH (2x20 mL) and Et<sub>2</sub>O (2x20 mL) to give **5** (2.56 g, 35%) as a light tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.22 (s, 9H), 8.50 (s, 1H), 10.27 (bs, 1H), 13.35 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 27.4, 40.3, 84.1, 111.8, 115.1, 138.2, 151.4, 153.5, 153.8, 176.5.

# 2,4-Diamino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 6

Pyrimidine-2,4,6-triamine (800 mg, 6.39 mmol) was added to a solution of NaOAc (1.10 g, 13.43 mmol) in distilled water (20 mL) and stirred at 50 °C until near total dissolution. A solution of 2-chloro-3-oxopropanenitrile (794 mg, 7.67 mmol) in H<sub>2</sub>O (10 mL) was added dropwise over 1 h to the reaction mixture. Then stirred 16 h at 50 °C, and subsequently, the mixture was refluxed for 1 h. After cooling to room temperature the reaction was cooled to 0 °C for 2 h. The obtained black solid was boiled in MeOH (4 mL) and washed with hot MeOH (2x4 mL). The remaining solid was refluxed in H<sub>2</sub>O (5 mL) and washed with hot H<sub>2</sub>O (5 mL) to yield **34** (91 mg, 8%) as a dark solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 5.89 (bs, 2H), 6.17 (bs, 2H), 7.68 (s, 1H), 11.82 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 82.5, 94.6, 117.4, 129.4, 154.3, 157.8, 161.7; HRMS (ESI) calculated for for C<sub>7</sub>H<sub>5</sub>N<sub>6</sub> [M'H]<sup>-</sup> 173.0581, found 173.0581.

#### Journal of Medicinal Chemistry

# 2-Amino-4-(methylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 7 (Procedure A\*)

**5** (100 mg, 0.52 mmol), methylamine (8M solution in EtOH) (53 mg, 0.20 mL, 1.70 mmol) and *N*,*N*-dimethylaniline (94 mg, 0.1 mL, 0.77 mmol) were suspended in dry 1,4-dioxane (2 mL) and heated for 20 min at 200 °C in the microwave reactor. After cooling to room temperature the reaction mixture was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*\*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 4CV; 0-5% 10CV; 5% 4CV) yielded **7** (20 mg, 21%) as a pale cream solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 2.92 (d, *J* = 4.6 Hz, 3H), 5.94 (bs, 2H), 6.05 (q, *J* = 4.6 Hz, 1H), 7.67 (s, 1H), 11.73 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 28.3, 82.3, 94.8, 117.4, 129.1, 153.6, 157.3, 161.5; HRMS (ESI) calculated for for C<sub>8</sub>H<sub>9</sub>N<sub>6</sub> [M<sub>+</sub>H]<sup>+</sup> 189.0883, found 189.0883; HPLC *t*R = 4.09 min (Method A).

# 2-Amino-4-((cyclopropylmethyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 8

# (Procedure B)

**5** (0.109 g, 0.39 mmol) and cyclopropanemethylamine (0.105 mL, 1.21 mmol) in 1,4-dioxane (2 mL, anhydrous) in a microwave vial was heated to 200 °C for 20 mins. The resulting solution was then diluted with EtOH (6 mL) and KOH (2 pellets) was added and the reaction mixture was heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure, the residue was suspended in water and the mixture was pH adjusted to pH 5.5, extracted into EtOAc, dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The resulting solid was triturated with Et<sub>2</sub>O and filtered to afford the title compound as an off-white solid (0.032 g, 0.14 mmol, 36 %).<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  0.29 (m, 2H), 0.44 (m, 2H), 1.16 (m, 1H), 3.32 (m, 2H), 5.90 (t, *J* = 5.4 Hz, 1H), 5.96 (s, 2H), 7.69 (s, 1H), 11.82 (br s, 1H). HRMS (ESI) calculated for C<sub>11</sub>H<sub>13</sub>N<sub>6</sub> 229.1194, found 229.1196.

# 2-Amino-4-(cyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 9

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 4CV; 0-2% 12CV) yielded **11** (35 mg, 26%) as a pale cream solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 1.22-1.28 (m, 1H), 1.30-1.37 (m, 4H), 1.54-1.57 (m, 32

1H), 1.67-1.70 (m, 2H), 1.91-1.93 (m, 2H), 4.01-4.08 (m, 1H), 5.32 (d, J = 8.0 Hz, 1H), 5.92 (bs, 2H), 7.66 (s, 1H), 11.80 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 24.8, 25.7, 32.8, 48.3, 81.8, 94.6, 117.7, 128.7, 153.6, 156.0, 161.6; HRMS (ESI) calculated for for C<sub>13</sub>H<sub>17</sub>N<sub>6</sub> [M<sup>+</sup>H]<sup>+</sup> 257.1509, found 257.1504; HPLC tR = 11.09 min (Method A).

### 2-Amino-4-(cyclohexylmethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 10

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: EtOAc /Hex, gradient: 25% 4CV; 25-100% 10CV; 100% 6CV) yielded **9** (27 mg, 19%) as a pale cream solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 0.91-1.01 (m, 2H), 1.13-1.23 (m, 3H), 1.54-1.65 (m, 2H), 1.68-1.74 (m, 4H), 3.32 (m, 2H), 5.75 (t, J = 5.7 Hz, 1H), 5.94 (bs, 2H), 7.68 (s, 1H), 11.82 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 26.0, 26.7, 31.0, 38.0, 46.4, 82.0, 94.8, 117.6, 128.9, 153.6, 157.0, 161.6; HRMS (ESI) calculated for for C<sub>14</sub>H<sub>17</sub>N<sub>6</sub> [M-H]<sup>-</sup> 269.1520, found 269.1519; HPLC *t*R = 11.83 min (Method A).

#### 2-Amino-4-(phenylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 11

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: EtOAc/Hex, gradient: 25% 4CV; 25-100% 10CV; 100% 6CV) yielded **11** (37 mg, 29%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 6.20 (bs, 2H), 7.00-7.04 (m, 1H), 7.30-7.33 (m, 2H), 7.68-7.70 (m, 2H), 7.68-7.70 (m, 1H), 8.03 (bs, 1H), 11.86 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 82.8, 96.0, 117.3, 120.8, 122.8, 129.2, 130.3, 140.5, 154.5, 154.6, 161.2; HRMS (ESI) calculated for for C<sub>13</sub>H<sub>9</sub>N<sub>6</sub> [M<sup>-</sup>H]<sup>-</sup> 249.0894, found 249.0891; HPLC *t*R = 9.85 min (Method A).

#### 4-((2-Amino-5-cyano-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino)benzoic acid 12

**5** (0.103 g, 0.37 mmol) and methyl-4-aminobenzoate (0.166 g, 1.1 mmol) in 1,4-dioxane (2 mL, anhydrous) in a 2-5 mL microwave vial was heated to 200 °C for 20 mins. Ethanol (4 mL) was added to the reaction mixture and KOH (1 pellet) was added and the mixture heated to 80 °C for 24 h. The reaction mixture was concentrated under reduced pressure, water was added and the mixture was

#### **Journal of Medicinal Chemistry**

pH adjusted to pH 5 with acid. The resulting white precipitate was filtered under reduced pressure, dried in an oven to afford the title compound as a white solid (0.0135 g, 0.05 mmol, 13%). <sup>1</sup>H NMR (DMSO- $d_6$ ):  $\delta$  6.33 (br s, 2H), 7.88 (m, 5H), 8.57 (s, 1H), 12.08 (br s, 1H), 12.61 (br s, 1H).HRMS (ESI) calculated for C<sub>14</sub>H<sub>11</sub>O<sub>2</sub>N<sub>6</sub> 295.0938, found 295.0938.

# 4-((2-Amino-5-cyano-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)amino)benzenesulfonamide 13

Prepared according to procedure B. The remaining solid was triturated with cold H<sub>2</sub>O (2x2 mL), filtered, dried and then triturated with Et<sub>2</sub>O (2x3 mL) to yield **13** as an off-white solid (0.0096 g, 0.03 mmol, 8 %).<sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  6.63 (br s, 2H), 7.55 (br s, 2H), 7.80 (m, 4H), 8.13 (s, 1H), 12.38 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>12</sub>O<sub>2</sub>N<sub>7</sub>S 330.0768, found 330.0768.

# 2-Amino-4-(benzylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 14

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: EtOAc/Hex, gradient: 80% 4CV; 80-100% 4CV; 100% 13 4CV; then MeOH/EtOAc, gradient: 0-10% 4CV) yielded **14** (53 mg, 39%) as a light tan solid.

<sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 4.69 (d, J = 5.9 Hz, 1H), 5.96 (bs, 2H), 6.48 (t, J = 5.9 Hz, 1H), 7.23-7.38 (m, 5H), 7.71 (s, 1H), 11.85 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 43.7, 82.2, 94.6, 117.4, 127.2, 127.9, 128.89, 129.4, 140.7, 153.9, 156.6, 161.5; HRMS (ESI) calculated for C<sub>14</sub>H<sub>11</sub>N<sub>6</sub> [M<sup>-</sup>H]<sup>-</sup> 263.10507, found 263.10489; HPLC tR = 10.05 min (Method A).

# 2-Amino-4-(2-morpholinoethylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 15

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 4CV; 0-10% 12CV; 10% 6CV) yielded **15** (23 mg, 31%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 2.42-2.46 (m, 4H), 2.54-2.57 (m, 2H), 3.50-3.54 (m, 2H), 3.61-3.63 (m, 4H), 5.98 (bs, 2H), 6.17 (t, J = 4.7 Hz, 1H), 7.69 (s, 1H), 11.82 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 36.9, 53.5, 56.7, 66.8, 82.1, 94.8, 117.4, 128.9, 153.6, 156.5, 161.7; HRMS (ESI) calculated for C<sub>13</sub>H<sub>16</sub>ON<sub>7</sub> [M<sup>•</sup>H]<sup>-</sup> 286.1422, found 286.1421; HPLC tR = 3.25 min (Method B).

# 2-Amino-4-(2-hydroxyethylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 16

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 6CV; 0-10% 12CV; 10% 6CV) yielded **16** (16 mg, 24%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.52-3.58 (m, 4H), 4.86 (t, J = 4.6 Hz, 1H), 5.89 (t, J = 5.1 Hz, 1H), 5.97 (bs, 2H), 7.29 (s, 1H), 11.83 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 42.9, 60.2, 82.0, 94.6, 117.3, 129.0, 153.5, 156.7, 161.3, HRMS (ESI) calculated for C<sub>9</sub>H<sub>10</sub>ON<sub>6</sub> [M<sup>+</sup>H]<sup>+</sup> 219.0989, found 219.0987; HPLC tR = 2.79 min (Method A).

# 2-Amino-4-(piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 17

Prepared according to procedure B. The remaining solid was triturated with cold H<sub>2</sub>O (2x2 mL), filtered, dried and then triturated with Et<sub>2</sub>O (2x3 mL) to yield **17** (43 mg, 49%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.62-1.65 (m, 6H), 3.52-3.57 (m, 4H), 6.02 (bs, 2H), 7.83 (s, 1H), 11.95 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 24.7, 26.00, 49.2, 84.1, 95.9, 118.2, 131.1, 155.6, 159.8, 160.6; HRMS (ESI) calculated for C<sub>12</sub>H<sub>16</sub>N<sub>6</sub> [M+H]<sup>+</sup> 243.1353, found 243.1349; HPLC *t*R = 9.63 min (Method A).

# 1-(2-Amino-5-cyano-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)piperidine-4-sulfonamide 18

**5** (105 mg, 0.38 mmol), piperidine-4-sulfonic acid amide hydrochloride (139 mg, 0.85 mmol) and triethylamine (0.16 mL, 1.15 mmol) in 1,4-dioxane (2.5 mL) was degassed under nitrogen prior to being irradiated with microwaves at 200 °C for 20 min. Once cooled to room temperature the reaction mixture was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the reaction mixture was heated to 90 °C for 22 h. The reaction mixture was then concentrated under reduced pressure, water was added and the mixture was adjusted to pH 5.5 with 1M HCl. This was then extracted into EtOAc and the organics were dried over MgSO<sub>4</sub>, filtered and concentrated under reduced pressure. The crude material was then purified by column chromatography (using 100% hexane – 100% EtOAc as eluent) to afford the title compound **18** as a white solid (26.1 mg, 0.08 mmol, 21 %). <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>):  $\delta$  1.73 (m, 2H), 2.09 (d, *J* = 8.4 Hz, 2H), 3.00 (t, *J* = 9.4 Hz, 2H), 3.11 (m, 1H), 4.32 (d, *J* = 10.4 Hz, 2H).

2H), 6.06 (br s, 2H), 6.80 (br s, 2H), 7.85 (s, 1H), 11.99 (br s, 1H). HRMS (ESI) calculated for  $C_{12}H_{14}O_2N_7S$  320.0935, found 320.0938.

# 2-Amino-4-morpholino-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 19

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 4CV; 0-2% 10CV) yielded **21** (40 mg, 32%) as a pale cream solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 3.53-3.55 (m, 4H), 3.73-3.75 (m, 4H), 6.13 (bs, 2H), 7.88 (s, 1H), 11.78 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 49.0, 66.5, 83.7, 96.2, 118.3, 131.5, 155.7, 159.8, 160.7; HRMS (ESI) calculated for C<sub>11</sub>H<sub>11</sub>ON<sub>6</sub> [M-H]<sup>-</sup> 243.0999, found 243.0997; HPLC tR = 6.84 min (Method A).

# 2-Amino-4-(4-methylpiperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 20

Prepared according to procedure B. The remaining solid was triturated with cold H<sub>2</sub>O (2x2 mL), filtered, dried and then triturated with Et<sub>2</sub>O (2x3 mL) to yield **20** (63 mg, 68%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 2.23 (s, 3H), 2.45 (app t, *J* = 4.8 Hz, 4H), 3.55 (app t, *J* = 4.8 Hz, 4H), 6.09 (bs, 2H), 7.86 (s, 1H), 11.96 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 27.5, 48.0, 54.9, 83.8, 95.9, 118.1, 131.3, 155.6, 159.5, 160.5; HRMS (ESI) calculated for C<sub>12</sub>H<sub>14</sub>N<sub>7</sub> [M-H]<sup>-</sup> 256.1316, found 256.1317; HPLC *t*R = 1.75 min (Method C).

# 2-Amino-4-(4-phenylpiperazin-1-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile 21

Prepared according to procedure B. The remaining solid was triturated with cold H<sub>2</sub>O (2x2 mL), filtered, dried and then triturated with Et<sub>2</sub>O (2x3 mL) to yield **21** (83 mg, 85%) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 3.29 (app t, *J* = 4.8 Hz, 4H), 3.71 (app t, *J* = 4.8 Hz, 4H), 6.06 (bs, 2H), 6.79-6.83 (m, 1H), 6.99-7.01 (m, 2H), 7.22-7.24 (m, 2H), 7.87 (s, 1H), 12.04 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 48.3, 48.7, 83.2, 96.7, 116.1, 118.7, 119.7, 129.6, 132.9, 151.5, 156.5, 159.7, 160.5; HRMS (ESI) calculated for C<sub>17</sub>H<sub>18</sub>N<sub>7</sub> [M+H]<sup>+</sup> 320.1618, found 320.1614; HPLC *t*R = 11.09 min (Method A).

# 2-Amino-4-(4-(2-hydroxyethyl)piperazin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 22

Prepared according to procedure B. The remaining solid was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: 5% NH<sub>4</sub>OH in MeOH/EtOAc, gradient: 10% 4CV; 10-25% 10CV; 25% 4CV) yielded product X (51 mg, 40%) yielded a gum which was triturated with acetone (2x1 mL) to afford **22** (72 mg, 70%) as a pale yellow solid <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 2.46 (app t, *J* = 6.2 Hz, 2H), 2.56-2.58 (m, 4H), 3.53-3.58 (m, 6H), 4.42 (bs, 1H), 6.04 (bs, 2H), 7.84 (s, 1H), 11.94 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 47.6, 52.9, 58.5, 60.2, 83.3, 95.3, 117.6, 130.7, 155.1, 158.9, 160.0; HRMS (ESI) calculated for C<sub>13</sub>H<sub>16</sub>ON<sub>7</sub> [M-H]<sup>-</sup> 286.1422, found 286.1422; HPLC *t*R = 7.24 min (Method C).

# 2-Amino-4-(3-hydroxypropylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 23

Prepared according to procedure B. The remaining solid was triturated with cold H<sub>2</sub>O (2x2 mL), filtered, dried and then triturated with Et<sub>2</sub>O (2x3 mL) to yield **23** (62 mg, 74%) as a pale cream solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.70-1.76 (m, 2H), 3.48-3.55 (m, 4H), 4.66 (t, *J* = 4.3 Hz, 1H), 5.95 (bs, 2H), 6.08 (t, *J* = 5.1 Hz, 1H), 7.68 (s, 1H), 11.82 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 32.6, 38.5, 59.6, 82.2, 94.7, 117.3, 129.1, 153.6, 156.8, 161.5; HRMS (ESI) calculated for C<sub>10</sub>H<sub>12</sub>NO [M-H]<sup>-</sup> 231.1000, found 231.1001; HPLC *t*R = 3.66 min (Method A).

# (R)-2-amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 24

**5** (100 mg, 0.36 mmol), (3R)-3-Hydroxypyrrolidine (0.2 mL, 2.48 mmol) and TEA (0.15 mL, 1.13 mmol) in dioxane (2.5 mL) was heated in the microwave at 200 °C for 20 minutes. The reaction mixture was then diluted with EtOH (8 mL), KOH (2 pellets) added and heated at 90 °C for 24 h. The reaction mixture was concentrated at reduced pressure, water (5 mL) added, acidified to pH 5.7 (3 M HCl) and extracted with EtOAc (10 mL x 3). The organic fractions were combined, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give the crude product. The crude was triturated with Et<sub>2</sub>O to afforded **24** (28 mg, 0.11 mmol, 33 %). <sup>1</sup>H NMR (500 MHz, DMSO-*d*<sub>6</sub>): d 1.85-1.94 (m, 1H), 1.94-2.04 (m, 1H), 3.56-3.64 (m, 1H), 3.70-3.85 (m, 3H), 4.39 (s, 1H), 4.99 (br s, 1H), 5.81 (s, 2H), 7.79 (s, 1H), 11.88 (br s, 1H), <sup>13</sup>C NMR (125 MHz, DMSO-*d*<sub>6</sub>): d

 33.0, 46.7, 57.3, 68.7, 83.4, 93.7, 118.6, 130.9, 154.7, 155.5, 159.8. HRMS: calculated for C<sub>11</sub>H<sub>13</sub>ON<sub>6</sub> 245.1145 [M+H]<sup>+</sup>, found 245.1143.

# (R)-2-Amino-4-(3-hydroxypyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 25

Prepared according to procedure A. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 6CV; 0-10% 12CV; 10% 6CV) yielded **25** (10 mg, 13%) as a light brown solid.  $[\alpha]_D^{20}$ : -21.50 (c = 0.37, DMSO),;<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.85-1.92 (m, 1H), 1.94-2.03 (m, 1H), 3.58-3.61 (m, 1H), 3.70-3.83 (m, 3H), 4.36-4.41 (m, 1H), 5.01 (d, *J* = 3.4 Hz, 1H), 5.84 (bs, 2H), 7.80 (s, 1H), 11.84 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 33.6, 47.3, 57.9, 69.3, 84.0, 94.3, 119.2, 131.5, 155.3, 156.0, 160.4; HRMS (ESI) calculated forC<sub>11</sub>H<sub>11</sub>ON<sub>6</sub> [M-H]<sup>-</sup>243.1000, found 243.1001; HPLC *t*R = 7.85 min (Method C).

# (R)-2-Amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile

# 

Prepared according to procedure B. The residue was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/DCM, gradient: 0% 4CV; 0-5% 4CV; 5% 4CV; 5-10% 4CV; 10% 4CV) yielded **26** (62 mg, 67%) as fluffy off-white solid.  $[\alpha]_D^{20}$ : -96.30 (c = 0.55, DMSO); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.83-1.89 (m, 1H), 1.90-1.96 (m, 2H), 2.02-2.10 (m, 1H), 3.52-3.63 (m, 2H), 3.70-3.76 (m, 1H), 3.86-3.91 (m, 1H), 4.46-4.51 (m, 1H), 4.77 (t, *J* = 5.0 Hz, 1H), 5.81 (bs, 2H), 7.81 (d, *J* = 1.0 Hz, 1H), 11.89 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 24.6, 27.5, 51.1, 60.4, 62.3, 84.3, 94.5, 119.3, 131.6, 155.4, 156.2, 160.2; HRMS (ESI) calculated forC<sub>12</sub>H<sub>15</sub>ON<sub>6</sub> [M+H]<sup>+</sup> 259.1302, found 259.1299; HPLC *t*R = 7.26 min (Method A).

# (*S*)-2-Amino-4-(2-(hydroximethyl)pyrrolidin-1-yl)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile

Prepared according to procedure B. The residue was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system:

MeOH/DCM, gradient: 0% 4CV; 0-5% 4CV; 5% 4CV; 5-10% 4CV; 10% 4CV) yielded **27** (68 mg, 73%) as fluffy off-white solid.  $[\alpha]_D^{20}$ : -93.80 (c = 0.54, DMSO); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.83-1.89 (m, 1H), 1.90-1.96 (m, 2H), 2.02-2.10 (m, 1H), 3.52-3.63 (m, 2H), 3.70-3.76 (m, 1H), 3.86-3.91 (m, 1H), 4.46-4.51 (m, 1H), 4.77 (t, *J* = 5.0 Hz, 1H), 5.81 (bs, 2H), 7.81 (d, *J* = 1.0 Hz, 1H), 11.89 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 24.6, 27.5, 51.1, 60.4, 62.3, 84.3, 94.5, 119.3, 131.6, 155.4, 156.2, 160.2; HRMS (ESI) calculated forC<sub>12</sub>H<sub>15</sub>ON<sub>6</sub> [M+H]<sup>+</sup> 259.1302, found 259.1298; HPLC *t*R = 7.26 min (Method A).

# 2-Amino-4-((1R,4R)-4-hydroxycyclohexylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 28

Prepared according to procedure B. The remaining solid was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/EtOAc, gradient: 0% 6CV; 0-15% 16CV; 15% 8CV) yielded a beige solid which was triturated with MeOH (0.5 mL) to yield **28** (32 mg, 35%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.26-1.34 (m, 2H), 1.41-1.52 (m, 2H), 1.83-1.88 (m, 2H), 1.92-1.98 (m, 2H), 3.41-3.49 (m, 1H), 3.97-4.08 (m, 1H), 6.67 (bs, 1H), 7.31 (bs, 2H), 7.85 (s, 1H), 12.68 (bs 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 30.2, 34.2, 49.5, 68.4, 84.3, 94.6, 116.2, 130.5, 147.1, 158.0, 160.4; HRMS (ESI) calculated for C<sub>13</sub>H<sub>15</sub>ON<sub>6</sub> [M+H]<sup>+</sup> 271.1313, found 271.1316; HPLC *t*R = 6.54 min (Method A).

# 2-Amino-4-(cyclohexyl(2-hydroxyethyl)amino)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 29

Prepared according to procedure B. The remaining solid was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/DCM, gradient: 0% 4CV; 0-5% 4CV; 5% 4CV; 5-10% 4CV; 10% 4CV) yielded **29** (51 mg, 40%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.05-1.14 (m, 1H), 1.36-1.45 (m, 2H), 1.53-1.61 (m, 3H), 1.71-1.77 (m, 4H), 3.44-3.48 (m, 2H), 3.54-3.49 (m, 1H), 4.16-4.21 (m, 1H), 4.55 (t, *J* = 5.4 Hz, 1H), 5.91 (bs, 2H), 7.84 (s, 1H), 11.95 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 25.4, 25.7, 31.1, 44.9, 58.9, 60.5, 84.2, 95.4, 118.2, 131.5, 155.8, 158.7, 160.1; HRMS (ESI) calculated forC<sub>15</sub>H<sub>19</sub>ON<sub>6</sub> [M-H]<sup>-</sup> 299.1626, found 299.1628; HPLC *t*R = 9.46 min (Method A).

# 2-Amino-4-((1RS,2SR,3RS)-2,3-dihydroxycyclopentylamino)-7H-pyrrolo[2,3-d]pyrimidine-5-

# carbonitrile 30

**5** (80 mg, 0.29 mmol), **37** (70 mg, 0.35 mmol) and Et<sub>3</sub>N (0.04 mL, 29 mg, 0.29 mmol) were suspended in *n*-BuOH (4 mL) and refluxed for 16 h. After cooling to room temperature EtOH (4 mL) and KOH (3 pellets) were added and the reaction mixture was heated at 80 °C for 20 h. The mixture was neutralised using 6M HCl and subsequently concentrated *in vacuo*. The remaining solid was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 50g cartridge, solvent system: MeOH/CHCl<sub>3</sub>, gradient: 0% 4CV; 0-15% 14CV; 15% 4CV) yielded **30** (33 mg, 42%) as a white solid.

<sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.29-1.38 (m, 1H), 1.47-1.55 (m, 1H), 1.87-1.96 (m, 1H), 2.18-2.27 (m, 1H), 3.72-3.75 (m, 1H), 3.89-3.93 (m, 1H), 4.28-4.36 (m, 1H), 4.39 (d, *J* = 3.3 Hz, 1H), 4.94 (d, *J* = 5.5 Hz, 1H), 5.66 (d, *J* = 7.1 Hz, 1H), 5.99 (bs, 2H), 7.69 (s, 1H), 11.83 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 27.0, 28.8, 55.4, 70.6, 77.8, 81.5, 94.2, 116.9, 128.4, 153.0, 156.5, 160.8; HRMS (ESI) calculated for C<sub>12</sub>H<sub>13</sub>O<sub>2</sub>N<sub>6</sub> [M+H]<sup>+</sup> 273.1105, found 273.1107; HPLC *t*R = 4.47 min (Method A).

# 2-Amino-4-((1*R*,2*S*,3*R*,4*S*)-2,3,4-trihydroxycyclopentylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5carbonitrile 31

**5** (70 mg, 0.25 mmol), **42** (146 mg, 0.30 mmol) and Et<sub>3</sub>N (0.08 mL, 61 mg, 0.60 mmol) were suspended in *n*-BuOH (4 mL) and refluxed for 16 h. After cooling to room temperature EtOH (4 mL) and KOH (3 pellets) were added and the reaction mixture was heated at 80 °C for 20 h. The mixture was neutralised using 6M HCl and subsequently concentrated *in vacuo*. The remaining solid was suspended in MeOH, adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: 5% NH<sub>4</sub>OH in MeOH/CHCl<sub>3</sub>, gradient: 2% 6CV; 2-15% 12CV; 10% 15CV) yielded a beige solid which was further triturated with MeOH (0.2 mL) and Et<sub>2</sub>O (2 mL) to yield **31** (24 mg, 33%) as a white solid.  $[\alpha]_D^{20}$ : -25.7° (c = 0.12, DMSO); <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.23-1.29 (m, 1H), 2.5-2.551 (m, 1H), 3.67-3.68 (m, 1H), 3.80-3.81 (m, 1H),

3.91-3.93 (m, 1H), 4.30-4.36 (m, 1H), 4.58 (d, J = 3.6 Hz, 1H), 4.91 (bs, 1H), 4.92 (bs, 1H), 5.70 (d, J = 7.5 Hz, 1H), 5.99 (bs, 2H), 7.69 (s, 1H), 11.83 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 37.8, 55.2, 74.6, 76.8, 77.6, 94.1, 117.0, 128.5, 129.5, 153.1, 156.2, 160.9; HRMS (ESI) calculated forC<sub>12</sub>H<sub>15</sub>O<sub>3</sub>N<sub>6</sub> [M+H]<sup>+</sup> 291.1200, found 291.1189; HPLC tR = 6.40 min (Method B).

# 3-(N,N-dibenzylamino)cyclopent-1-ene 34

A mixture of cyclopentene (12.3 mL, 9.18 g, 0.135 mol), NBS (6.01 g, 33.71 mmol) and benzoyl peroxide (70%, 163 mg, 0.67 mmol) in CCl<sub>4</sub> (21 mL) was heated at reflux for 1 h. The reaction mixture was cooled to 0 °C, filtered through a pad of Celite® (eluent CCl<sub>4</sub>) and solvent and cyclopentene were distilled off *in vacuo*. The residue was dissolved in CCl<sub>4</sub> (30 mL), cooled to 0 °C and *N*,*N*-dibenzylamine (16.2 mL, 16.60 g, 84.28 mmol) was added to the crude solution of bromide **33**. The mixture then warmed to room temperature and stirred for 30 min. The reaction mixture was then filtered, heated to 40 °C, and stirred at this temperature for 1 h, then filtered and stirred at room temperature for 16 h. The mixture was then filtered and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 100g cartridge, solvent system: 10% Et<sub>2</sub>O in Hex/Hex, gradient: 0% 4CV; 0-10% 10CV) yielded **34** (6.23 g, 70%) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.78-1.93 (m, 2H), 2.22-2.29 (m, 1H), 2.34-2.41 (m, 1H), 3.43 (d, *J* = 13.8 Hz, 2H), 3.64 (d, *J* = 13.8 Hz, 2H), 4.03-4.05 (m, 1H), 5.75-5.76 (m, 1H), 5.86-5.89 (m, 1H), 7.19-7.23 (m, 2H), 7.27-7.31 (m, 4H), 7.37-7.39 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 23.4, 31.9, 54.5, 66.1, 126.8, 128.3, 128.8, 132.1, 133.3, 140.8.

#### (1RS,2SR,3RS)-3-(dibenzylamino)cyclopentane-1,2-diol 35

A solution of OsO<sub>4</sub> in H<sub>2</sub>O (4% w/v, 0.32 mL, 13 mg, 0.05 mmol) was added to a stirred solution of **51** (1.31 g, 4.98 mmol) and NMO (1.33 g, 14.94 mmol) in acetone/H<sub>2</sub>O (4:1, 35 mL) and the resultant mixture was stirred at room temperature for 4 h. Sat. aq. Na2SO3 (5 mL) was then added and the solution was stirred for an additional 30 min. Acetone was evaporated *in vacuo*, H<sub>2</sub>O (10 mL) was added and the aqueous layer was extracted with DCM (3x20 mL). The organic layer was adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 50 g cartridge,

#### **Journal of Medicinal Chemistry**

solvent system: EtOAc/Hex, gradient: 10% 4CV; 10-20% 6CV; 20% 4CV; 20-60% 6CV; 60% 6CV) yielded **35** (1.06 g, 72%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.52-1.75 (m, 2H), 1.83-1.96 (m, 2H), 2.28 (bs, 1H), 2.37 (bs, 1H), 3.27 (app q, J = 8.4 Hz, 1H), 3.57 (d, J = 13.9 Hz, 2H), 3.78 (d, J = 13.9 Hz, 2H), 3.92 (app dd, J = 8.2, 5.2 Hz, 1H), 3.99-4.05 (m, 1H), 7.21-7.25 (m, 2H), 7.29-7.32 (m, 4H), 7.35-7.37 (m, 4H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 19.6, 29.0, 55.0, 65.1, 71.1, 74.6, 127.1, 128.4, 128.7, 139.9; HRMS (ESI) calculated for C<sub>19</sub>H<sub>24</sub>O<sub>2</sub>N [M+H]<sup>+</sup> 298.1802, found 298.1798.

# (1RS,2SR,3RS)-3-(dibenzylamino)cyclopentane-1,2-diyl-dibenzoate 36

Benzoyl chloride (1.62 ml, 1.96 g, 13.92 mmol) was added dropwise to a stirred solution of **35** (1.03 g, 3.48 mmol) in dry pyridine (30 mL) at 0 °C, left to warm to room temperature and stirred for 1 day. Pyridine was evaporated *in vacuo* and the residue was suspended in Et2O (40 mL), cooled to 0 °C followed by addition of saturated aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was then washed with saturated aqueous NaHCO<sub>3</sub> (3x20 mL) and subsequently adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: 10% Et<sub>2</sub>O in Hex/Hex, gradient: 0% 3CV; 0-10% 3CV; 10% 4CV; 10-20% 4CV; 20% 4CV; 20-40% 6CV) yielded **36** (1.45 g, 84%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.75-1.84 (m, 1H), 1.88-1.96 (m, 1H), 2.01-2.10 (m, 1H), 2.18-2.26 (m, 1H), 3.67 (d, *J* = 13.8 Hz, 2H), 3.77 (d, *J* = 13.8 Hz, 2H), 3.78-3.86 (m, 1H), 5.54 (dt, *J* = 5.0, 4.6 Hz, 1H), 5.67 (dd, *J* = 8.0, 5.0 Hz, 1H), 7.20-7.40 (m, 14 H), 7.49 (m, 1H), 7.55 (m, 1H), 7.76 (dd, *J* = 8.4, 1.3 Hz, 2H), 7.94 (dd, *J* = 8.4, 1.3 Hz, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 20.7, 27.6, 54.7, 62.2, 73.3, 74.0, 126.9, 128.3, 128.3, 128.4, 128.7, 129.6, 129.8, 130.1, 130.2, 132.9, 133.0, 139.7, 165.7, 165.9; HRMS (ESI) calculated for C<sub>33</sub>H<sub>32</sub>O<sub>4</sub>N [M+H]<sup>+</sup> 506.2326, found 506.2321.

# (1RS,2SR,3RS)-3-aminocyclopentane-1,2-diyl dibenzoate 37

 $Pd(OH)_2/C$  (20% w/w, 700 mg) was added to a vigorously stirred solution of **36** (1.42 g, 2.81 mmol) in EtOH/EtOAc (5:1, 60 mL) and the resultant suspension was stirred at room temperature under H2 (1 atm) for 16 h. The suspension was filtered through a Celite® pad (eluent MeOH) and concentrated

*in vacuo*. The residue was triturated with Et<sub>2</sub>O (2x20 mL) to give **37** (908 mg, 98%) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 1.73-1.82 (m, 1H), 1.93-2.02 (m, 1H), 2.32-2.43 (m, 2H), 3.93 (app dt, J = 8.0, 7.6 Hz, 1H), 5.49 (dd, J = 7.5, 5.1 Hz, 1H), 5.59-5.63 (m, 1H), 7.42-7.49 (m, 4H), 7.61-7.66 (m, 2H), 7.86-7.89 (m, 2H), 8.38 (bs, 2H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 25.2, 27.7, 53.4, 73.2, 76.6, 129.1, 129.2, 129.6, 129.7, 129.8, 129.9, 134.1, 134.1, 165.4, 165.5; HRMS (ESI) calculated for C<sub>19</sub>H<sub>20</sub>O<sub>4</sub>N [M+H]<sup>+</sup> 326.1387, found 326.1382.

#### Di-tert-butyl-[(1R,4S)-4-hydroxycyclopent-2-en-1-yl]imidodicarbonate 39

A suspension of sodium di-*tert*-butyl-iminodicarboxylate, previously prepared by reaction of di-*tert*-butyl-iminodicarboxylate (1.195 g, 5.50 mmol) with NaH (60% suspension in mineral oil) (132 mg, 5.50 mmol) in dry THF (18 mL), was cannulated to a room temperature solution of (1R,4S)-4-hydroxycyclopent-2-enyl acetate (521 mg, 3.67 mmol), PPh<sub>3</sub> (144 mg, 0.55 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (636 mg, 0.55 mmol) in dry THF / DMF (1:1) (16 mL). The reaction mixture was heated at 50 °C for 1 day, then diluted with MeOH (10 mL) and dry loaded on to silica. Chromatographic purification (Biotage SP4, 50 g cartridge, solvent system: EtOAc/Hex, gradient: 0% 4CV; 0-20% 10CV, 20% 6CV) yielded **39** (463 mg, 42%) as a colorless oil that solidifies upon standing to afford a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.48 (s, 18H), 1.83 (dt, *J* = 15.1, 2.3 Hz, 1H), 2.68 (ddd, *J* = 15.1, 9.3, 7.9 Hz, 1H), 3.20 (bs, 1H), 4.57-4.61 (m, 1H), 5.09 (app dq, *J* = 9.3, 2.3 Hz, 1H), 5.74 (dd, *J* = 5.4, 2.3 Hz, 1H), 6.04 (dt, *J* = 5.4, 2.3 Hz, 1H), <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.1, 38.9, 60.3, 75.8, 82.9, 131.5, 136.9, 153.4.

#### Di-tert-butyl-[(1R,2S,3R,4S)-2,3,4-trihydroxycyclopentyl] imidodicarbonate 40

A solution of  $OsO_4$  in  $H_2O$  (4% w/v, 0.06 mL, 3 mg, 0.01 mmol) was added to a solution of **39** (120 mg, 0.40 mmol) and NMO (141 mg, 1.20 mmol) in a 4:1 mixture acetone /  $H_2O$  (10 mL). The solution was stirred at room temperature for 1 day. Saturated aqueous  $Na_2SO_3$  (5 mL) was added and the reaction mixture was stirred for 30 min. Acetone was removed *in vacuo* and the aqueous layer was extracted with EtOAc (4 x 20 mL). The organic layer was adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: EtOAc/DCM,

#### **Journal of Medicinal Chemistry**

gradient: 20% 6CV; 20-80% 8CV; 80% 8CV) yielded **40** (71 mg, 53%) as a colorless oil that solidifies upon standing to afford a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.49 (s, 18H), 1.79-1.85 (m, 1H), 2.53-2.62 (m, 1H), 2.91 (bs, 3H), 3.98-3.99 (m, 1H), 4.01-4.04 (m, 1H), 4.39-4.45 (m, 1H), 4.55-4.58 (m, 1H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.0, 34.1, 61.9, 74.9, 75.1, 77.3, 83.6, 153.7; HRMS (ESI) calculated for C<sub>15</sub>H<sub>27</sub>O<sub>7</sub>NNa [M+Na]<sup>+</sup> 356.1680, found 356.1682.

#### (1S,2R,3S,4R)-4-(Bis(tert-butoxycarbonyl)amino)cyclopentane-1,2,3-triyl tribenzoate 41

Benzoyl chloride (0.33 ml, 397 mg, 2.83 mmol) was added dropwise to a stirred solution of **40** (235 mg, 0.71 mmol) in dry pyridine (6 mL) at 0 °C. Left to warn to room temperature and stirred for 1 day. Pyridine was evaporated *in vacuo* and the residue was partitioned between Et<sub>2</sub>O (40 mL) and saturated aqueous NaHCO<sub>3</sub> (10 mL). The organic layer was separated and washed with saturated aqueous NaHCO<sub>3</sub> (3x20 mL) and subsequently adsorbed on silica gel and concentrated *in vacuo*. Chromatographic purification (Biotage SP4, 50g cartridge, solvent system: Et<sub>2</sub>O/Hex, gradient: 0% 6CV; 0-20% 10CV; 20% 6CV) yielded **41** (338 mg, 74%) as a colorless oil that solidified upon standing to afford a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 1.51 (s, 18H), 2.21-2.29 (m, 1H), 2.75-2.82 (m, 1H), 5.00-5.07 (m, 1H), 5.58-5.64 (m, 1H), 5.98-6.05 (m, 2H), 7.29-7.34 (m, 4H), 7.41-7.51 (m, 3H), 7.54-7.63 (m, 2H), 7.90-7.93 (m, 4H), 8.08-8.13 (m, 2H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$ : 28.1, 30.3, 58.3, 73.7, 74.3, 75.6, 83.3, 128.3, 128.4, 128.5, 129.4, 129.4, 129.6, 129.7, 129.8, 129.9, 133.1, 133.1, 133.2, 152.5, 165.3, 165.4, 166.0; HRMS (ESI) calculated for C<sub>36</sub>H<sub>39</sub>O<sub>10</sub>NNa [M+Na]<sup>+</sup> 668.2463, found 668.2463.

#### (1S,2R,3S,4R)-4-Aminocyclopentane-1,2,3-triyl-tribenzoate hydrochloride 42

**41** (297 mg, 0.46 mmol) was placed in an oven-dry round bottom flask, purged with N<sub>2</sub>, cooled to 0 °C and subsequently treated with 4M HCl in 1,4-dioxane (10 mL). The mixture was left to warm to room temperature, stirred for 16 h and concentrated *in vacuo*. The residue was triturated with Et<sub>2</sub>O (5x1 mL) to yield **42** (168 mg, 76%) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$ : 2.01-2.09 (m, 1H), 2.97-3.04 (m, 1H), 4.07-4.14 (m, 1H), 5.51-5.56 (m, 1H), 5.73-5.76 (m, 1H), 5.82-5.83 (m, 1H), 7.43-7.49 (m, 4H), 7.55-7.59 (m, 2H), 7.63-7.73 (m, 3H), 7.87-7.92 (m, 4H), 8.03-8.05 (m, 2H), 8.66

(bs, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ: 31.6, 51.6, 73.6, 74.6, 74.8, 129.0, 129.1, 129.2, 129.2, 129.3, 129.4, 129.8, 129.9, 134.2, 164.9, 165.2, 165.4; HRMS (ESI) calculated forC<sub>26</sub>H<sub>24</sub>O<sub>6</sub>N [M+H]<sup>+</sup> 446.1598, found 446.1599.

# 2-Amino-4-phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 43

**5** (96 mg 0.35 mmol), phenyl boronic acid (73 mg, 0.60 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (0.041 g, 0.047 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.19 mL, 1.81 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.3, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate) and triturated with diethyl ether to afford the title compound **43** as a light brown solid (4.9 mg, 0.0208 mmol, 6.0 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.63 (br s, 2H), 7.54 -7.55 (m, 3H), 7.78-7.80 (m, 2H), 8.12 (s, 1H), 12.40 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>9</sub>N<sub>5</sub> [M+H]<sup>+</sup> 236.0931, found 236.0930.

# 2-Amino-4-(4-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimdine-5-carbonitrile 44

**5** (115 mg, 0.42 mmol), 4-hydroxyphenyl boronic acid (92 mg, 0.67 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (49 mg, 0.042 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.18 mL, 1.71 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The reaction mixture was then concentrated under reduced pressure and the resulting solid was triturated with methanol, filtered and dried. EtOH (9 mL) was added KOH (2 pellets) and the mixture heated to 90 °C for 48 h. The reaction mixture was concentrated under reduced pressure, water was added and the mixture was pH adjusted to pH 6 and extracted into EtOAc. The organic layer was dried over MgSO<sub>4</sub> and concentrated under reduced pressure to afford the title compound **44** as a brown solid 10.1 mg, 0.040 mmol, 67 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.51 (br s, 2H), 6.89 (d, 2H, *J* = 8.4 Hz), 7.67 (d, 2H,

#### Journal of Medicinal Chemistry

J = 8.8 Hz), 8.08 (s, 1H), 9.90 (s, 1H), 12.28 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>9</sub>N<sub>5</sub>O 252.0880 [M+H]<sup>+</sup>, found 252.0880. HPLC: tR = 8.62 min (70.46 %).

# 2-Amino-4-(4-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 45

**5** (100 mg 0.31 mmol), Pd-118 (20 mg, 0.03 mmol), *t*-butylamine (160  $\mu$ L, 1.55 mmol) and 4-flurophenylboronic acid (69 mg, 0.5 mmol) were suspended in a 2:1 mixture *i*-PrOH/H<sub>2</sub>O (4.5 mL) and were irradiated with microwaves at 160 °C for 40 min. Once cooled to room temperature the reaction mixture was concentrated under reduced pressure. To this was added EtOH (5 mL) and KOH (2 pellets) and the reaction mixture was refluxed at 90 °C for 20 h. The mixture was then concentrated under reduced pressure, the crude material was then suspended in H<sub>2</sub>O and adjusted to pH 5 with 1M HCl. The solution was then extracted with EtOAc (2x50 mL); the organic layer was adsorbed on silica gel and concentrated under reduced pressure. Chromatographic purification (EtOAc/Hex: 50% 4CV, 50-75% 6CV, 75% 4CV, 75-100% 7CV, 100% 6CV) yielded a beige solid that was triturated with Et<sub>2</sub>O to afford the title compound **45** as a beige solid (13 mg, 0.05 mmol, 17 %). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  6.62 (s, 2H), 7.36 (t, *J* = 8.3 Hz, 2H), 7.83 (t, *J* = 7.7 Hz, 2H), 8.12 (s, 1H), 12.36 (s, 1H), HRMS: calcualated for C<sub>13</sub>H<sub>9</sub>N<sub>5</sub>F [M+H]<sup>+</sup> 254.0837, found 254.0831.

# 4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide 46

**5** (101 mg, 0.36 mmol), 4-aminocarbonyl phenylboronic acid (96 mg, 0.58 mmol), Pd(PPh<sub>3</sub>)<sub>4</sub> (40 mg, 0.035 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (6 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 30 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.2, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The mixture was then concentrated under reduced pressure, triturated with diethyl ether and methanol and filtered. The solid and filtrate were combined and purified by column chromatography (100% Hexane – 100 % Ethyl acetate). The isolated compound **46** as an off-white

solid (6 mg, 0.022 mmol, 5.9 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.68 (s, 2H), 7.51 (br s, 1H), 7.85 (d, 2H, *J* = 9.2 Hz), 8.40 (d, 2H, *J* = 10.4 Hz), 8.14 (br s, 1H), 8.16 (s, 1H), 12.40 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>8</sub>N<sub>6</sub>O [M+H]<sup>+</sup> 277.0843, found 277.0844. HPLC: *t*R = 7.94 min (Method A) (76.01 %).

# 2-Amino-4-(4-hydroxymethyl)phenyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 47

**5** (103 mg, 0.37 mmol), 4-hydroxymethyl)phenyl boronic acid (99 mg, 0.65 mmol), Pd-118 (47 mg, 0.072 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.3, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate) to afford the title compound **47** as an off-white solid (28.5 mg, 0.108 mmol, 29 %).<sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  4.61 (d, 2H, *J* = 5.6 Hz), 5.34 (t, 1H, *J* = 5.8 Hz), 6.60 (br s, 2H), 7.47 (d, 2H, *J* = 7.6 Hz), 7.77 (d, 2H, *J* = 8.0 Hz), 8.11 (s, 1H), 12.34 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>11</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 264.0891, found 264.0891. HPLC: *t*R = 8.45 min (Method A) (94.35 %).

# 4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide 48

**5** (100.6 mg, 0.36 mmol), 4-sulphamoylbenzene boronic acid (124 mg 0.62 mmol), Pd-118 (43 mg 0.066 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.195 mL, 1.86 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (6 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane –

#### Journal of Medicinal Chemistry

100 % Ethyl acetate) and triturated with diethyl ether to afford the title compound **48** as an off-white solid (19.1 mg, 0.0608 mmol, 17 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.70 (br s, 2H), 7.54 (br s, 2H), 7.97 (br s, 4H), 8.17 (s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>8</sub>N<sub>6</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 313.0513, found 313.0517. HPLC: *t*R = 8.33 min (Method A) (94.29 %).

# 2-Amino-4-(4-(methylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 49

5 (104 mg, 0.38 mmol), (4-methylsulphonyl)benzene boronic acid (128 mg, 0.64 mmol), Pd-118 (25 mg, 0.038 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.22 mL, 2.09 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 22 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.7, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate), triturated with diethyl ether, filtered and dried to afford the title compound **49** as a pale yellow solid (54.8 mg, 0.175 mmol, 47%). <sup>1</sup>H NMR (500 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  3.30 (br s, 3H), 6.67 (br s, 2H), 8.03 (d, 2H, *J* = 8.5 Hz), 8.09 (d, 2H, *J* = 8.5 Hz), 8.17 (s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>10</sub>N<sub>5</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 312.0561, found 312.0564. HPLC: *t*R = 8.97 min (Method A).

# N-(4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl)methanesulfonamide 50

**5** (0.103 g, 0.37 mmol), 4-(methylsulphonyl)aminobenzene boronic acid (0.121 g, 0.56 mmol), Pd-118 (0.027 g, 0.041 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 22 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.7, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate), triturated with diethyl ether, filtered and dried to afford the title compound **50** as a pale yellow solid (0.0399 g, 0.122 mmol, 32.7 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  3.08 (s, 3H), 6.55 (br s, 2H), 7.34 (d, 2H, *J* = 8.8 Hz), 7.78 (d, 2H, *J* = 8.4 Hz), 8.10 (s, 1H), 10.08 (br s, 1H), 12.33 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>11</sub>N<sub>6</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 327.0670, found 327.0673. HPLC: *t*R = 8.92 min (Method A) (85.80 %).

# 4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d/pyrimidin-4-yl)-N-(p-tolyl)benzenesulfonamide 51

**5** (100 mg, 0.36 mmol), 4-(*N*-*p*-tolylsulfamoyl)phenylboronic acid (168 mg, 0.58 mmol), Pd-118 (23 mg, 0.03 mmol) in IPA/H<sub>2</sub>O (3:1.5 mL) was degassed with nitrogen. *t*-Butylamine (0.19 mL, 1.8 mmol) was added and the mixture was heated in the microwave at 160 °C for 40 min. The reaction mixture was then diluted with EtOH (4 mL), KOH (2 pellets) added and heated at 90 °C for 24 h. The reaction mixture was concentrated under reduced pressure and the resulting mixture was suspended in water (5 mL), acidified to pH 5.7 (3 M HCl) and extracted with EtOAc (10 mL x 3). The organic fractions were combined, dried over anhydrous MgSO<sub>4</sub>, filtered and concentrated under reduced pressure to give the crude product. Purification by flash column chromatography (silica gel with EtOAc (75-100 %) in hexane afforded the title compound **51** as an off-white solid (0.005 g, 0.01 mmol, 3 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>): 2.18 (s, 3H), 6.69 (br s, 2H), 6.98 (d, 2H, *J* = 8.4 Hz), 7.03 (d, 2H, *J* = 8.4 Hz), 7.84 (d, 2H, *J* = 8.4 Hz), 7.88 (d, 2H, *J* = 8.4 Hz), 8.14 (s, 1H), 10.20 (s, 1H), 12.43 (br s, 1H). HRMS: calculated for C<sub>20</sub>H<sub>15</sub>O<sub>2</sub>N<sub>6</sub>S [M+H]<sup>+</sup> 403.0983, found 403.0986.

# 4-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)-N-methylbenzenesulfonamide 52

**5** (115 mg, 0.42 mmol), 4-((methylamino)sulphonyl)benzene boronic acid (134 mg 0.62 mmol), Pd-118 (32 mg, 0.049 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.22 mL, 2.09 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 22 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % 

#### Journal of Medicinal Chemistry

Hexane – 100 % Ethyl acetate), triturated with diethyl ether, filtered and dried to afford the title compound **52** as a pale yellow solid (47.2 mg, 0.144 mmol, 35 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  2.46 (d, 3H, *J* = 4.8 Hz), 6.71 (br s, 2H), 7.60 (q, 1H, *J* = 4.9 Hz), 7.92 (d, 2H, *J* = 8.0 Hz), 7.98 (d, 2H, *J* = 8.4 Hz), 8.16 (s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>11</sub>N<sub>6</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 327.0670, found 327.0674. HPLC: *t*R = 9.24 min (Method A) (82.18 %).

# 2-Amino-4-(3-hydroyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 53

**5** (113 mg, 0.41 mmol), 3-hydroxyphenyl boronic acid (95 mg, 0.69 mmol), Pd-118 (33 mg 0.051 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.22 mL, 2.09 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 22 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate) to afford the title compound **53** as an off-white solid (12 mg, 0.048 mmol, 11.7 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.58 (br s, 2H), 6.91 (d, 1H, *J* = 8.0 Hz), 7.15-7.19 (m, 2H), 7.31 (t, 1H, *J* = 7.6 Hz), 8.09 (s, 1H), 9.62 (s, 1H), 12.33 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>7</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 250.0734, found 250.0737. HPLC: *t* R = 8.75 min (Method A).

### 2-Amino-4-(3-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 54

**5** (104 mg, 0.38 mmol), 3-fluorobenzene boronic acid (85 mg, 0.61 mmol) and Pd(PPh<sub>3</sub>)<sub>4</sub> (45 mg, 0.039 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.16 mL, 1.52 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The reaction mixture was then concentrated under reduced pressure and the resulting solid was triturated with methanol, filtered and dried to give the intermediate compound as an off-white solid (28.3 mg, 0.084 mmol, 22%). EtOH (10 mL) was added KOH (2 pellets) and the mixture heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure and suspended in water. The mixture

was then pH adjusted to pH 5.8 and extracted into EtOAc (2 x 100 mL), dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The resulting solid was triturated with diethyl ether, filtered and dried to afford the title compound **54** as an off-white solid (12.2 mg, 0.048 mmol, 58%). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.67 (br s, 2H), 7.39 (t, 1H, J = 7.5 Hz), 7.55-7.63 (m, 3H), 8.15 (s, 1H), 12.40 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>8</sub>N<sub>5</sub>F [M+H]<sup>+</sup> 254.0837, found 254.0833. HPLC: *t*R = 10.42 min (Method A) (90.05 %).

# 3-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimdin-4-yl)benzamide 55

**5** (112 mg, 0.40 mmol), 3-(aminocarbonyl)phenyl boronic acid (108 mg, 0.65 mmol), Pd-118 (37 mg, 0.056 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.21 mL, 2.0 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 24 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate – 5% Methanol/Ethyl acetate) to afford the title compound **55** as a yellow solid (34.2 mg, 0.123 mmol, 30 %).<sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.67 (br s, 2H), 7.45 (br s, 1H), 7.61 (t, 1H, J = 7.6 Hz), 7.91 (d, 1H, J = 7.6 Hz), 8.01-8.05 (m, 2H), 8.14 (s, 1H), 8.30 (br s, 1H), 12.45 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>9</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 277.0843, found 277.0846. HPLC: tR = 8.17 min (Method A) (46.30 %).

# 2-Amino-4-(3-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 56

**5** (103 mg, 0.37 mmol), 3-(hydroxymethyl)phenyl boronic acid (94 mg, 0.62 mmol), Pd-118 (53 mg, 0.081 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 20 h. The reaction mixture was then concentrated under reduced pressure and the

#### Journal of Medicinal Chemistry

resulting mixture was suspended in water, pH adjusted to pH 5.5, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate), triturated with diethyl ether, filtered and dried to afford the title compound **56** as a yellow solid (30.5 mg g, 0.115 mmol, 31%). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  4.60 (d, 2H, *J* = 4.4 Hz), 5.28 (t, 1H, *J* = 5.2 Hz), 6.60 (br s, 2H), 7.49 (br s, 2H), 7.65-7.66 (m, 1H), 7.74 (s, 1H), 8.11 (s, 1H), 12.20 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>9</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 264.0891, found 264.0894. HPLC: *t*<sub>R</sub> = 8.62 min (Method A).

# 3-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide 57

**5** (102 mg g, 0.37 mmol), 3-(aminosulphonyl)benzene boronic acid (122 mg, 0.61 mmol), Pd-118 (24 mg, 0.037 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 24 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.7, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate) to afford the title compound **57** as a pale solid (43.2 mg, 0.138 mmol, 38%). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.74 (br s, 2H), 7.44 (br s, 2H), 7.74 (t, 1H, *J* = 7.8 Hz), 8.00 (t, 2H, *J* = 7.2 Hz), 8.17 (s, 1H), 8.23 (br s, 1H), 12.45 (br s, 1H).HRMS (ESI) calculated for C<sub>13</sub>H<sub>9</sub>N<sub>6</sub>S [M+H]<sup>+</sup> 313.0513, found 313.0516. HPLC: *t* = 8.44 min (Method A) (93.47 %).

# 2-Amino-4-(2-hydroxyphenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 58

**5** (117 mg, 0.36 mmol), 2-hydroxybenzene boronic acid (94 mg, 0.68 mmol), Pd-118 (26 mg, 0.040 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.20 mL, 1.90 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 24 h. The reaction mixture was then concentrated under reduced pressure and the resulting

mixture was suspended in water, pH adjusted to pH 5.3, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The mixture was then concentrated under reduced pressure, triturated with diethyl ether and purified by column chromatography (100 % Hexane-100 % Ethyl acetate). The resulting solid was triturated with diethyl ether, filtered under reduced pressure and dried to afford the title compound **58** as a bright yellow solid (30.7 mg, 0.122 mmol, 34 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.99 (t, 1H, *J* = 7.5 Hz), 7.07 (d, 1H, *J* = 8.0 Hz), 7.46 (d of t, 1H, *J* = 1.5, 7.0 Hz), 7.56 (d of d, 1H, *J* = 2.0, 1.5 Hz), 8.36 (s, 1H). HRMS (ESI) calculated for C<sub>15</sub>H<sub>10</sub>N<sub>2</sub>O<sub>2</sub> [M+H]<sup>+</sup> 250.0737, found 250.0735. HPLC: *t*R = 10.11 min (Method A).

# 2-Amino-4-(2-fluorophenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 59

**5** (100 mg, 0.31 mmol), Pd-118 (20 mg, 0.03 mmol), *t*-butylamine (160  $\mu$ L, 1.55 mmol) and 2-flurophenylboronic acid (69 mg, 0.5 mmol) were suspended in a 2:1 mixture *i*-PrOH/H<sub>2</sub>O (4.5 mL) and were irradiated with microwaves at 160 °C for 40 min. Once cooled to room temperature the reaction mixture was concentrated under reduced pressure. To this was added EtOH (5 mL) and KOH (2 pellets) and the reaction mixture was refluxed t at 90 °C for 20 h. The mixture was then concentrated under reduced pressure, the crude material was then suspended in H<sub>2</sub>O and adjusted to pH 5 with 1M HCl. The solution was then extracted with EtOAc (2x50 mL); the organic layer was adsorbed on silica gel and concentrated under reduced pressure. Chromatographic purification (EtOAc/Hex: 50% 4CV, 50-75% 6CV, 75% 4CV, 75-100% 7CV, 100% 6CV) yielded a beige solid that was triturated with Et<sub>2</sub>O to afford the title compound **59** and as a beige solid (16 mg g, 0.06 mmol, 20 %). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  6.68 (s, 2H), 7.35 (t, *J* = 8.3 Hz, 2H), 7.58 (t, *J* = 7.7 Hz, 2H), 8.06 (s, 1H), 12.34 (s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>9</sub>N<sub>5</sub>F [M+H]<sup>+</sup> 254.0837 found 254.0831.

# 2-(2-Amino-5-cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzamide 60

5 (104 mg, 0.32 mmol), 2-(aminocarbonyl)benzne boronic acid (87 mg, 0.53 mmol), Pd-118 (21 mg, 0.032 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.18 mL, 1.71 mmol) was added and the mixture was irradiated at 160 °C for 40 min. The resulting 53

#### Journal of Medicinal Chemistry

solution was diluted with EtOH (8 mL) and KOH (2 pellets) were added and the mixture was heated to 90 °C for 24 h. The reaction mixture was then concentrated under reduced pressure and the resulting mixture was suspended in water, pH adjusted to pH 5.3, extracted into EtOAc (2 x 100 mL) and dried over MgSO<sub>4</sub>. The mixture was then concentrated under reduced pressure, triturated with methanol and purified by column chromatography (100 % Hexane - 10 % Methanol/Ethyl acetate). The resulting solid was recrystallised from dichloromethane and diethyl ether, and dried to afford the title compound **60** as a bright yellow solid (3.5 mg, 0.0126 mmol, 3.9 %). <sup>1</sup>H NMR (400 Hz, DMSO*d*<sub>6</sub>):  $\delta$  6.48 (br s, 2H), 7.23 (s, 1H), 7.40-7.42 (m, 1H), 7.51-7.60 (m, 2H), 7.71 (d, 1H, *J* = 2.2 Hz), 7.73 (br s, 1H), 7.96 (s, 1H), 12.20 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>9</sub>N<sub>6</sub>O [M+H]<sup>+</sup> 277.0843, found 277.0851. HPLC: *t*R = 7.86 min (Method A) (88.64 %).

# 2-Amino-4-(2-(hydroxymethyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-5-carbonitrile 61

**5** (110 mg, 0.40 mmol), 2-hydroxymethylbenzne boronic acid (133 mg, 0.87 mmol), Pd-118 (31 mg, 0.048 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.21 mL, 2.0 mmol) was added and the mixture was irradiated at 160 °C for 40 min. Organics were combined and concentrated under reduced pressure. The resulting solid was triturated with diethyl ether, filtered and dried to afford the title compound **61** as an off-white solid (51 mg g, 0.193 mmol, 49 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  4.55 (d, 2H, *J* = 5.6 Hz), 5.09 (t, 1H, *J* = 5.8 Hz), 6.64 (br s, 2H), 7.37-7.41 (m, 2H), 7.48 (d of t, 1H, *J* = 2.0, 7.2 Hz), 7.61 (d, 1H, *J* = 7.6 Hz), 8.05 (s, 1H), 12.31 (br s, 1H). HRMS (ESI) calculated for C<sub>14</sub>H<sub>10</sub>N<sub>5</sub>O [M+H]<sup>+</sup> 264.0891, found 264.0891.

# 2-(2-Amino-5-cyano-7*H*-pyrrolo[2,3-*d*]pyrimidin-4-yl)benzenesulfonamide 62

**5** (130 mg, 0.405 mmol), 2-(sulfamoylphenyl)boronic acid (130 mg, 0.65 mmol) and Pd-118 (28 mg, 0.043 mmol) was suspended in a mixture of IPA/H<sub>2</sub>O (3 mL:1.5 mL) and the mixture was degassed under nitrogen. *t*-Butylamine (0.25 mL, 2.4 mmol) was added and the reaction mixture was degassed under nitrogen. The reaction mixture was irradiated with microwaves at 160 °C for 40 min. Once cooled to room temperature the mixture was diluted with EtOH (8 mL) and KOH (2 pellets) added.

#### Journal of Medicinal Chemistry

The reaction mixture was heated to 95 °C for 20 hh. The reaction mixture was then concentrated under reduced pressure. The residue was suspended in water and the mixture was pH adjusted to pH 5.5 and extracted with ethyl acetate and concentrated under reduced pressure. The resulting solid was triturated with diethyl ether and filtered off. Further purification was required and this was carried out using HPLC to afford the title compound **62** (6.8 mg). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  6.82 (br s, 2H), 7.16 (br s, 2H), 7.62 (m, 1H), 7.73 (m, 2H), 8.04 (m, 1H), 8.06 (d, *J* = 5.0 Hz, 1H), 12.39 (br s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>11</sub>N<sub>6</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 315.0659, found 315.0656.

# 4-(2-Amino-7H-pyrrol[2,3-d]pyrimidin-4-yl)benzenesulfonamide 64

4-Chloro-7*H*-pyrrolo[2,3-*d*]pyrimdin-2-amine (70 mg, 0.42 mmol), 4-sulphamoylbenzne boronic acid (133 mg, 0.66 mmol), Pd-118 (37 mg, 0.057 mmol) were suspended in a mixture of IPA/H<sub>2</sub>O (3:1.5 mL) and degassed. *t*-Butylamine (0.22 mL, 2.09 mmol) was added and the mixture was irradiated at 160 °C for 40 min. Once cooled to room temperature the reaction mixture was diluted with ethyl acetate and concentrated under reduced pressure. The resulting solid was purified by column chromatography (100 % Hexane – 100 % Ethyl acetate), triturated with diethyl ether, filtered and dried to afford the title compound **64** as a pale yellow solid (23.7 mg, 0.082 mmol, 20 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  6.23 (br s, 2H), 6.61 (d, 1H, *J* = 2.0 Hz), 7.17 (d, 1H, *J* = 2.8 Hz), 7.48 (br s, 2H), 7.98 (d, 2H, *J* = 8.4 Hz), 8.2 (d, 2H, *J* = 8.4 Hz), 11.36 (br s, 1H). HRMS (ESI) calculated for C<sub>12</sub>H<sub>11</sub>N<sub>5</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 290.0706, found 290.0703. HPLC: *t*R = 8.45 min (Method A).

# 4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide 65

6-Chloro-7-deazapurine (233 mg, 1.45 mmol), 4-sulfamoylbenzene boronic acid (408 mg, 2.03 mmol) and 2-amino-2-methylpropane (0.61 mL, 5.80 mmol) were dissolved in 2-propanol (7.5 mL) and water (3.75 mL) and the solution degassed with argon. Dichloro[1,1' bis(di-*tert*-butylphosphino)]ferrocene palladium (II) (94.4 mg, 0.145 mmol) was added and the mixture was heated at 160°C for 40 min in a microwave. The reaction mixture was concentrated under reduced pressure and purified by flash column chromatography (silica gel with EtOAc (100 %) – 50 %

#### Journal of Medicinal Chemistry

MeOH/EtOAc) to give the crude product. Trituration of the crude product with DCM/MeOH (9:1) gave the title compound **65** as a yellow solid (155 mg, 0.57 mmol, 39 %). <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ): 6.95 (d, 1H, J = 2.0 Hz), 7.52 (s, 2H), 7.27 (dd, 1H, J = 2.8, 2.0 Hz), 8.04 (d, 2H, J = 8.4 Hz), 8.37 (d, 2H, J = 8.4 Hz), 8.89 (s, 1H), 12.41 (br s, 1H). HRMS (ESI) calculated for C<sub>12</sub>H<sub>10</sub>N<sub>4</sub>O<sub>2</sub>S [M+H]<sup>+</sup> 275.0603, found 275.0597.

# 4-(5-Cyano-7H-pyrrolo[2,3-d]pyrimidin-4-yl)benzenesulfonamide 66

4-Chloro-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carbonitrile (95 mg, 0.53 mmol), 4-sulfamoylphenylboronic acid (171 mg, 0.85 mmol) and Pd-118 (35mg, 0.05) was suspended in a mixture of IPA/H<sub>2</sub>O (3 mL:1.5 mL) and the mixture was degassed under nitrogen. *t*-Butylamine (0.28 mL, 2.7 mmol) was added and the reaction mixture was degassed under nitrogen. The reaction mixture was irradiated with microwaves at 160 °C for 1 h. The reaction mixture was cooled to room temperature and the crude material was suspended in methanol, adsorbed onto silica gel and concentrated under reduced pressure. Purification was achieved using column chromatography (100% hexane – 50/50 hexane/ethyl acetate – 100% ethyl acetate) to afford the title compound **66** as a beige solid (76 mg, 0.25 mmol, 48%). <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>):  $\delta$  7.58 (s, 2H), 8.03 (d, *J* = 8.0 Hz, 2H), 8.08 (d, *J* = 8.3 Hz, 2H), 8.73 (s, 1H), 9.06 (s, 1H), 13.52 (s, 1H). HRMS (ESI) calculated for C<sub>13</sub>H<sub>10</sub>O<sub>2</sub>N<sub>5</sub>S [M+H]<sup>+</sup> 300.0550, found 300.0546.

# 4-(Piperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine 67

4-Chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-2-amine (80 mg, 4.76 mmol), NEt<sub>3</sub> (0.2 mL, 1.43 mmol) and piperidine (0.15 mL, 1.52 mmol) was suspended in 1,4-dioxane (2.5 mL) which was degassed under nitrogen. The reaction mixture was irradiated with microwaves at 200 °C for 20 min. The resulting mixture was diluted with EtOAc (10 mL) and concentrated under reduced pressure. Purification by column chromatography (100% EtOAc – 10% MeOH/EtOAc) followed by trituration with diethyl ether and filtration afforded the title compound **67** as a white solid (8 mg, 0.04 mmol, 0.8 %).<sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  1.56 (m, 4H), 1.64 (m, 2H), 3.75 (t, J = 5.0 Hz, 4H), 5.49 (br s, 2H), 6.31 (dd,

J = 2.0, 3.5 Hz, 1H), 6.72 9dd, J = 2.5, 3.5 Hz, 1H), 10.80 (br s, 2H).HRMS (ESI) calculated for  $C_{11}H_{16}N_5 [M+H]^+ 218.1400$ , found 218.1398.

# N<sup>4</sup>-Cyclohexyl-7*H*-pyrrolo[2,3-*d*]pyrimidine-2,4-diamine 68

To 2-amino-3*H*-pyrrolo[2,3-*d*]pyrimidin-4(7*H*)-one (110 mg, 0.73 mmol), BOP (44 mg, 1.00 mmol) and DBU (0.22 mL, 1.47 mmol) in DMF/DMSO (1:1, 4 mL) was added cyclohexylamine (0.25 mL, 2.19 mmol) at room temperature. The reaction mixture was stirred at room temperature for 4 d then heated to 60 °C for 2 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was triturated with water and extracted into EtOAc. The organic layer was concentrated under reduced pressure to afford the title compound **68** as an yellow solid (50 mg, 0.22 mmol, 30 %). <sup>1</sup>H NMR (400 Hz, DMSO-*d*<sub>6</sub>):  $\delta$  1.14 (m, 1H), 1.35 (m, 4H), 1.63 (m, 2H), 1.76 (m, 2H), 1.90 (m, 2H), 6.49 (br s, 2H), 6.63 (s, 1H), 6.85 (s, 1H), 7.36 (br s, 1H), 11.71 (br s, 1H). LRMS (ESI): calculated for C<sub>12</sub>H<sub>17</sub>N<sub>5</sub> [M+H]<sup>+</sup> 232.29, found 232.27.

# (1R,4R)-4-(2-Amino-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino) cyclohexanol 69

Prepared according to procedure B using 4-chloro-7*H*-pyrrolo[2,3-*d*]pyrimidin-2-amine. Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: MeOH/DCM, gradient: 5% 4CV; 0-20% 10CV; 20% 4CV) yielded **69** (94 mg, 64%) as a fluffy white solid.

Mp: 178-180 °C (d); <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 1.20-1.36 (m, 4H), 1.84-1.90 (m, 4H), 3.37-3.44 (m, 1H), 3.91-4.01 (m, 1H), 4.54 (d, J = 4.4 Hz, 1H), 5.38 (bs, 2H), 6.31-6.32 (m, 1H), 6.59-6.60 (m, 1H), 6.63 (bs, 1H), 10.57 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 31.4, 35.0, 48.0, 69.1, 96.5, 99.4, 117.0, 153.2, 156.6, 160.3; HRMS (ESI) calculated for C<sub>12</sub>H<sub>18</sub>ON<sub>5</sub> [M+H]<sup>+</sup> 248.1506, found 248.1504; HPLC tR = 7.40 min (Method C).

# N<sup>4</sup>-Cyclohexyl-5-(trifluoromethyl)-7*H*-pyrrolo[2,3-*d*]pyrimidine-2,4-diamine 70

Prepared according to procedure A using 4-chloro-5-(trifluoromethyl)-7*H*-pyrrolo[2,3-*d*]pyrimidin-2amine (100 mg, 0.42 mmol). Chromatographic purification (Biotage SP4, 10 g cartridge, solvent system: EtOAc/ Hex, gradient: 15% 4CV; 15-75% 10CV; 75% 6CV) yielded a brown oil. The oil was

#### Journal of Medicinal Chemistry

dissolved in Et2O (1 mL) and poured dropwise into Hex (6 mL). The precipitate was filtered off to yield **70** (30 mg, 24%) as a light brown solid. Mp: 202-204 °C (d); <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ : 1.11-1.20 (m, 3H), 1.25-1.37 (m, 2H), 1.58-1.62 (m, 1H), 1.70-1.74 (m, 2H), 1.88-1.91 (m, 2H), 3.70-3.80 (m, 1H), 6.91 (d, J = 7.3 Hz, 1H), 7.09 (bs, 2H), 7.99 (s, 1H); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$ : 25.3, 25.9, 33.1, 49.0, 59.3, 100.0, 105.5, 121.8, 123.9, 147.6, 151.6; HRMS (ESI) calculated for C<sub>13</sub>H<sub>16</sub>N<sub>5</sub>F<sub>3</sub> [M-H]<sup>-</sup> 298.1285, found 298.1283; HPLC *t*R = 10.76 min (Method A).

# 2-Amino-4-((1*R*,4*R*)-4-hydroxycyclohexylamino)-7*H*-pyrrolo[2,3-*d*]pyrimidine-5-carboxamide

**5** (100 mg, 0.56 mmol) and *trans*-4-aminocyclohexanol (124 mg, 1.08 mmol) were suspended in *n*-BuOH (4 mL) and refluxed for 16 h. After cooling to room temperature H<sub>2</sub>O (2 mL) and KOH (2 pellets) were added and the reaction mixture was heated for 40 min at 150 °C in the microwave oven. The mixture was neutralised using 6M HCl and concentrated *in vacuo*. The residue was triturated with H2O (4 mL) and dried *in vacuo*. The remaining solid was then triturated with Et<sub>2</sub>O (2x10 mL) and dried *in vacuo* to afford **71** (91 mg, 87% yield) as a beige solid. Mp: >300 °C (d); FTIR (neat): 3441.8, 3352.4, 3130.0, 2938.5, 2854.5, 1628.5, 1593.6, 1507.5, 1451.01, 1417.06 cm-1; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 1.18-1.32 (m, 4H), 1.83-1.85 (m, 2H), 1.95-1.98 (m, 2H), 3.43-3.53 (m, 1H), 3.88-3.96 (m, 1H), 4.54 (d, *J* = 2.6 Hz, 1H), 5.56 (bs, 2H), 7.00 (bs, 1H), 7.50 (s, 1H), 7.65 (bs, 1H), 9.37 (d, *J* = 7.7 Hz, 1H), 11.16 (bs, 1H); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$ : 30.7, 33.9, 47.4, 68.4, 95.0, 111.1, 122.1, 154.0, 157.0, 161.1, 168.0; HRMS (ESI) calculated for C<sub>13</sub>H<sub>19</sub>O<sub>2</sub>N<sub>6</sub> [M+H]<sup>+</sup> 291.1564, found 291.1563; HPLC *t*R = 6.64 min (Method C).

# **IKK Assays**

IKKα and IKKβ inhibitory activity was determined using a dissociation enhanced ligand fluorescent immunoassay (DELFIA) based on the protocol of HTScan<sup>™</sup> IKKβ Kinase Assay (Cell Signaling Technology, USA).

Recombinant IKK $\alpha$  or IKK $\beta$ , 37 nM, (Millipore, Dundee, UK) was incubated with I $\kappa$ B- $\alpha$  (Ser32) (New England Biolabs, Hitchin, UK) biotinylated peptide substrate (0.375  $\mu$ M) and 40  $\mu$ M ATP in assay buffer (40 mM Tris-HCl (pH 7.5), 20 mM MgCl<sub>2</sub>, EDTA 1 mM, DTT 2 mM and BSA 0.01 mg/ml) in a V-well 96-well plate in the presence and absence of test compound. The assay plate was incubated for 60 minutes at 30 °C after which the kinase reaction was quenched by the addition of 50mM EDTA, pH8. The resulting mixture was transferred to a streptavidin coated 96-well plate (Perkin Elmer, Beaconsfield, UK) and incubated for 1 hour at 30 °C to immobilise the substrate peptide. After three washes with wash buffer (0.01 M phosphate buffered saline (PBS), 0.05% Tween -20, pH 7.4) a primary antibody against the phosphorylated substrate (phospho-I $\kappa$ B- $\alpha$ ) (Ser32/36) (5A5) Mouse mAb (New England Biolabs, Hitchin, UK) (1:1000 dilution with 1% bovine serum albumin (BSA) in wash buffer) was added and incubated at 37 °C for 2 h.

After a further three washes, a secondary europiated antibody (Eu-N1 labelled anti-mouse IgG, (Perkin Elmer, Beaconsfield, UK) diluted 1:500 in 1% BSA/ wash buffer) was added and incubated at 30 °C for 30 minutes. After a further five washes, DELFIA enhancement solution - (Perkin Elmer, Beaconsfield UK) was added and allowed to incubate for 10 min at room temperature, protected from light, to facilitate the chemifluorescent detection. The relative fluorescence units (RFU) signal were measured on a Wallac Victor 1420 multilabel counter (Perkin Elmer, Beaconsfield, UK ), in time-resolved fluorescence mode. The counter was set at an excitation wavelength of 340 nm with a 400  $\mu$ s delay before detecting emitted light at 615 nm. The apparent K<sub>i</sub> of the phosphorylated substrate was calculated for each compound using the Cheng-Prusoff Equation.

# **Cell Culture**

U2OS cells were cultured with McCoy's 5A Modified Medium and MEF were cultured with DEME medium containing 10% (v/v) FCS and medium was changed every 2 d thereafter until cells became confluent. Cells were incubated at 37°C in humidified air with 5%  $CO_2$  and rendered quiescent by serum deprivation for 24 h prior to stimulation in serum-free medium.

# Western blot analysis

#### Journal of Medicinal Chemistry

Whole cell lysates were prepared from U2OS and status of  $I\kappa B\alpha$ , p65, p-p65 (Ser536) and p-p100 (Ser 866/870) assessed by Western blotting as described in Mackenzie et al (2007).<sup>46</sup>

# NFκB transcriptional activity assays

An adenoviral vector encoding NF $\kappa$ B-luciferase (Adv.NF $\kappa$ B-Luc) was purchased from Vector Biolabs (University of Pennsylvania, Philadelphia, US). Large-scale production of high titre recombinant adenovirus was performed by routine methods<sup>47</sup>. IKK $\beta$  knock-out Mouse Embryonic Fibroblasts (MEFs; kindly provided by Prof. I Verma , UCSD, USA) were counted when approximately 60-70% confluent in T75cm<sup>2</sup> flasks, and infected with adenovirus up to 300 p.f.u/cell<sup>-1</sup> for 24 h in 10% DMEM. Cells were then lifted from the flasks and plated into 96-well clear bottom, black luciferase plates and allowed to settle for 24 h before serum starved overnight. Cells were then stimulated with the appropriate agonists for the indicated times and reactions terminated by addition of lysis buffer containing 0.2 mM luciferin substrate. Relative light units (RLU) were measured using a Trilux microbeta counter (luminometer).

# **Kinase profiling**

Kinase profiling of compound **48** was outsourced to Millipore, specifically the Kinase profiler customer service for single concentration studies using duplicate assay points.

#### **Supporting Information**

Molecular formula strings with associated IKK biochemical inhibitory data in SMILES format. Coordinates (pdb format) for the IKK $\alpha$  homology model and related complexes with selected inhibitors (Compounds **4**, **9**, **43**, **47**, **48** and **50**). The inhibitory profile for compound **48** against 40 kinases.

# **Corresponding author**

\* Simon P. Mackay: simon.mackay@strath.ac.uk

# Acknowledgements

Financial support was provided by Cancer Research UK through grant no. C7599/A9336 and Prostate Cancer UK, grant no. PG12-27

# Abbreviations used

CDK2, cyclin dependent kinase 2; DELFIA, dissociation-enhanced lanthanide fluorescence immunoassay; FCS, fecal calf serum; GK, gatekeeper; G-loop, glycine-rich loop; IkB $\alpha$ , inhibitory kappa B  $\alpha$ ; IKK, inhibitory kappaB kinase; IL-1 $\beta$ , interleukin-1 $\beta$ ; MD, molecular dynamics; MEF, mouse embryonic fibroblasts; NAM, noraristeromycin; NF-kB, nuclear factor kappa-light-chainenhancer of activated B cells; RLU, relative light units; TNF $\alpha$ , tumour necrosis factor  $\alpha$ ; U2OS, human bone osteosarcoma cells.

# References

(1) Karin, M. Nuclear factor-kappa B in cancer development and progression. *Nature* 2006, *441*, 431-436.

(2) Xiao, C. C.; Ghosh, S. NF-kappa B, an evolutionarily conserved mediator of immune and inflammatory responses. In *Mechanisms of Lymphocyte Activation and Immune Regulation X: Innate Immunity*, Gupta, S.; Paul, W. E.; Steinman, R., Eds. Springer, Boston US, 2005; Vol. 560, pp 41-45.
(3) Häcker, H.; Karin, M. Regulation and function of IKK and IKK-related kinases. *Science's STKE*

, re13-re13 doi: 10.1126/stke.3572006re13.

(4) Xiao, G. T.; Rabson, A. B.; Young, W.; Qing, G. L.; Qu, Z. X. Alternative pathways of NF-kappa B activation: A double-edged sword in health and disease. *Cytokine Growth Factor Rev.* **2006**, *17*, 281-293.

(5) Hu, Y. L.; Baud, V.; Oga, T.; Kim, K. I. I.; Yoshida, K.; Karin, M. IKKalpha controls formation of the epidermis independently of NF-kappa B. *Nature* **2001**, *410*, 710-714.

(6) Karin, M.; Greten, F. R. NF kappa B: Linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* **2005**, *5*, 749-759.

#### Journal of Medicinal Chemistry

(7) Sizemore, N.; Lerner, N.; Dombrowski, N.; Sakurai, H.; Stark, G. R. Distinct roles of the IkappaB kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa-B) from IkappaB and in phosphorylating the p65 subunit of NF-kappa B. *J. Biol. Chem.* **2002**, *277*, 3863-3869.

(8) Park, K. J.; Krishnan, V.; O'Malley, B. W.; Yamamoto, Y.; Gaynor, R. B. Formation of an IKK alpha-dependent transcription complex is required for estrogen receptor-mediated gene activation. *Mol. Cell* **2005**, *18*, 71-82.

(9) Wen, D. Y.; Nong, Y. H.; Morgan, J. G.; Gangurde, P.; Bielecki, A.; DaSilva, J.; Keaveney, M.; Cheng, H.; Fraser, C.; Schopf, L.; Hepperle, M.; Harriman, G.; Jaffee, B. D.; Ocain, T. D.; Xu, Y. J. A selective small molecule IkappaB kinase beta inhibitor blocks nuclear factor kappa B- mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells. *J. Pharmacol. Exp. Ther.* **2006**, *317*, 989-1001.

(10) Burke, J. R.; Pattoli, M. A.; Gregor, K. R.; Brassil, P. J.; MacMaster, J. F.; McIntyre, K. W.; Yang, X. X.; Iotzova, V. S.; Clarke, W.; Strnad, J.; Qiu, Y. P.; Zusi, F. C. BMS-345541 is a highly selective inhibitor of IkappaB kinase that binds at an allosteric site of the enzyme and blocks NF-kappa B-dependent transcription in mice. *J. Biol. Chem.* **2003**, *278*, 1450-1456.

(11) Kim, B. H.; Lee, J. Y.; Seo, J. H.; Lee, H. Y.; Ryu, S. Y.; Ahn, B. W.; Lee, C. K.; Hwang, B. Y.; Han, S. B.; Kim, Y. Artemisolide is a typical inhibitor of IkappaB kinase beta targeting cysteine-179 residue and down-regulates NF-kappa B-dependent TNF-alpha expression in LPS-activated macrophages. *Biochem. Biophys. Res. Commun.* **2007**, *361*, 593-598.

(12) Podolin, P. L.; Callahan, J. F.; Bolognese, B. J.; Li, Y. H.; Carlson, K.; Davis, T. G.; Mellor, G. W.; Evans, C.; Roshak, A. K. Attenuation of murine collagen-induced arthritis by a novel, potent, selective small molecule inhibitor of IkappaB kinase 2, TPCA-1 (2-(aminocarbonyl)amino-5-(4-fluorophenyl)-3-thiophenecarboxamide), occurs via reduction of proinflammatory cytokines and antigen-induced T cell proliferation. *J. Pharmacol. Exp. Ther.* 2005, *312*, 373-381.

(13) Strnad, J.; Burke, J. R. IkappaB kinase inhibitors for treating autoimmune and inflammatory disorders: potential and challenges. *Trends Pharmacol. Sci.* **2007**, *28*, 142-148.

(14) Pasparakis, M. Regulation of tissue homeostasis by NF-kappa B signalling: implications for inflammatory diseases. *Nat. Rev. Immunol.* **2009**, *9*, 778-788.

(15) Li, Q. T.; Van Antwerp, D.; Mercurio, F.; Lee, K. F.; Verma, I. M. Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. *Science* **1999**, *284*, 321-325.

(16) Llona-Minguez, S.; Baiget, J.; Mackay, S. P. Small-molecule inhibitors of IkB kinase (IKK) and IKK-related kinases. *Pharm. Pat. Anal.* **2013**, *2*, 481-498.

(17) Asamitsu, K.; Yamaguchi, T.; Nakata, K.; Hibi, Y.; Victoriano, A. F. B.; Imai, K.; Onozaki, K.; Kitade, Y.; Okamoto, T. Inhibition of human immunodeficiency virus type 1 replication by blocking IkappaB Kinase with noraristeromycin. *J. Biochem.* **2008**, *144*, 581-589.

(18) Palayoor, S. T.; Youmell, M. Y.; Calderwood, S. K.; Coleman, C. N.; Price, B. D. Constitutive activation of IkappaB kinase alpha and NF-kappa B in prostate cancer cells is inhibited by ibuprofen. *Oncogene* **1999**, *18*, 7389-7394.

(19) Ammirante, M.; Luo, J. L.; Grivennikov, S.; Nedospasov, S.; Karin, M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. *Nature* **2010**, *464*, 302-U187.

(20) Ben-Neriah, Y.; Karin, M. Inflammation meets cancer, with NF-kappa B as the matchmaker. *Nat. Immunol.* **2011**, *12*, 715-723.

(21) Luo, J. L.; Tan, W.; Ricono, J. M.; Korchynskyi, O.; Zhang, M.; Gonias, S. L.; Cheresh, D. A.; Karin, M. Nuclear cytokine-activated IKKalpha controls prostate cancer metastasis by repressing Maspin. *Nature* **2007**, *446*, 690-694.

(22) Hao, L.; Rizzo, P.; Osipo, C.; Pannuti, A.; Wyatt, D.; Cheung, L. W. K.; Sonenshein, G.;
Osborne, B. A.; Miele, L. Notch-1 activates estrogen receptor-alpha-dependent transcription via
IKKalpha in breast cancer cells. *Oncogene* 2010, *29*, 201-213.

(23) Cao, Y. X.; Luo, J. L.; Karin, M. I kappa B kinase a kinase activity is required for self-renewal of ErbB2/Her2-transformed mammary tumor-initiating cells. *Proc. Natl. Acad. Sci. U. S. A.* **2007**, *104*, 15852-15857.

#### **Journal of Medicinal Chemistry**

(24) Cao, Y. X.; Bonizzi, G.; Seagroves, T. N.; Greten, F. R.; Johnson, R.; Schmidt, E. V.; Karin, M. IKKalpha provides an essential link between RANK signaling and cyclin D1 expression during mammary gland development. *Cell* **2001**, *107*, 763-775.

(25) Liou, G. Y.; Doppler, H.; Necela, B.; Krishna, M.; Crawford, H. C.; Raimondo, M.; Storz, P. Macrophage-secreted cytokines drive pancreatic acinar-to-ductal metaplasia through NF-kappa B and MMPs. *J. Cell Biol.* **2013**, *202*, 563-577.

(26) Storz, P. Targeting the alternative NF-kappa B pathway in pancreatic cancer: a new direction for therapy? *Expert Rev. Anticancer Ther.* **2013**, *13*, 501-504.

(27) Doppler, H.; Liou, G. Y.; Storz, P. Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. *Plos One* **2013**, *8*, e53676. doi:10.1371.

(28) Liu, S. P.; Misquitta, Y. R.; Olland, A.; Johnson, M. A.; Kelleher, K. S.; Kriz, R.; Lin, L. L.; Stahl, M.; Mosyak, L. Crystal Structure of a human IkappaB Kinase beta asymmetric dimer. *J. Biol. Chem.* **2013**, *288*, 22758-22767.

(29) Shrestha, S.; Bhattarai, B. R.; Cho, H.; Choi, J. K. PTP1B inhibitor ertiprotafib is also a potent inhibitor of IkappaB kinase beta (IKK-beta). *Biorg. Med. Chem. Lett.* **2007**, *17*, 2728-2730.

(30) Klepper, F.; Polborn, K.; Carell, T. Robust synthesis and crystal-structure analysis of 7-cyano-7-deazaguanine (PreQ(0) base) and 7-(aminomethyl)-7-deazaguanine (PreQ(1) base). *Helv. Chim. Acta* 2005, *88*, 2610-2616.

(31) Llona-Minguez, S.; Mackay, S. P. Stereoselective synthesis of carbocyclic analogues of the nucleoside Q precursor (PreQ(0)). *Beilstein J. Org. Chem.* **2014**, *10*, 1333-1338.

(32) Ziegler, K.; Schenck, G.; Krockow, E. W. The synthesis of cantharidin. *Justus Liebigs Ann. Chem.* **1942**, *551*, 1-79.

(33) Blades, K.; Donohoe, T. J.; Winter, J. J. G.; Stemp, G. A *syn* selective dihydroxylation of cyclic allylic trichloroacetamides using catalytic osmium tetroxide. *Tetrahedron Lett.* **2000**, *41*, 4701-4704.

(34) Lam, P. Y. S.; Clark, C. G.; Li, R. H.; Pinto, D. J. P.; Orwat, M. J.; Galemmo, R. A.; Fevig, J.

M.; Teleha, C. A.; Alexander, R. S.; Smallwood, A. M.; Rossi, K. A.; Wright, M. R.; Bai, S. A.; He,

K.; Luettgen, J. M.; Wong, P. C.; Knabb, R. M.; Wexler, R. R. Structure-based design of novel

guanidine/benzamidine mimics: Potent and orally bioavailable factor Xa inhibitors as novel anticoagulants. *J. Med. Chem.* **2003**, *46*, 4405-4418.

(35) Orsini, P.; Menichincheri, M.; Vanotti, E.; Panzeri, A. Highly efficient synthesis of 5-benzyl-3aminoindazoles. *Tetrahedron Lett.* **2009**, *50*, 3098-3100.

(36) Jones, G.; Willett, P.; Glen, R. C. Molecular recognition of receptor-sites using a genetic algorithm with a description of desolvation. *J. Mol. Biol.* **1995**, *245*, 43-53.

(37) Ghose, A. K.; Herbertz, T.; Pippin, D. A.; Salvino, J. M.; Mallamo, J. P. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. *J. Med. Chem.* **2008**, *51*, 5149-5171.

(38) Carbain, B.; Paterson, D. J.; Anscombe, E.; Campbell, A. J.; Cano, C.; Echalier, A.; Endicott, J.

A.; Golding, B. T.; Haggerty, K.; Hardcastle, I. R.; Jewsbury, P. J.; Newell, D. R.; Noble, M. E. M.; Roche, C.; Wang, L. Z.; Griffin, R. J. 8-Substituted *O*-6-Cyclohexylmethylguanine CDK2 inhibitors: Using structure-based inhibitor design to optimize an alternative binding mode. *J. Med. Chem.* **2014**, *57*, 56-70.

(39) Huang, W. C.; Hung, M. C. Beyond NF-kappa B activation: nuclear functions of IkappaB kinase alpha. *J. Biomed. Sci.* **2013**, *20* 3 doi:10.1186/1423-0127-20-3

(40) Leopizzi, M.; Cocchiola, R.; Milanetti, E.; Raimondo, D.; Politi, L.; Giordano, C.; Scandurra, R.; Scotto d'Abusco, A. IKKα inibition by a glucosamine derivative enhances Maspin expression in osteosarcoma cell line. *Chem.-Biol. Interact.* **2017**, *262*, 19-28.

(41) Solt, L. A.; Madge, L. A.; Orange, J. S.; May, M. J. Interleukin-1-induced NF-kappa B activation is NEMO-dependent but does not require IKK beta. *J. Biol. Chem.* **2007**, *282*, 8724-8733.

(42) Denk, A.; Goebeler, M.; Schmid, S.; Berberich, I.; Ritz, O.; Lindemann, D.; Ludwig, S.; Wirth, T. Activation of NF-kappa B via the I kappa B kinase complex is both essential and sufficient for proinflammatory gene expression in primary endothelial cells. *J. Biol. Chem.* **2001**, *276*, 28451-28458.

(43) Craft, J. W.; Legge, G. B. An AMBER/DYANA/MOLMOL phosphorylated amino acid library set and incorporation into NMR structure calculations. *J. Biomol. NMR* **2005**, *33*, 15-24.

### **Journal of Medicinal Chemistry**

(44) Talapatra, S. K.; Anthony, N. G.; Mackay, S. P.; Kozielski, F. Mitotic kinesin Eg5 overcomes inhibition to the phase I/II clinical candidate SB743921 by an allosteric resistance mechanism. *J. Med. Chem.* **2013**, *56*, 6317-6329.

(45) Ryckaert, J. P.; Ciccotti, G.; Berendsen, H. J. C. Numerical-integration of cartesian equations of motion of a system with constraints - molecular dynamics of *N*-alkanes. *J. Comput. Phys.* **1977**, *23*, 327-341.

(46) MacKenzie, C. J.; Ritchie, E.; Paul, A.; Plevin, R. IKK alpha and IKK beta function in TNF alpha-stimulated adhesion molecule expression in human aortic smooth muscle cells. *Cell. Signal.* **2007**, *19*, 75-80.

(47) Nicklin, S. A.; Baker, A. H. Simple methods for preparing recombinant adenoviruses for highefficiency transduction of vascular cells. In *Vascular Disease: Molecular Biology and Gene Therapy Protocols*, Baker, A. H., Ed. Humana Press: Totowa, NJ, 1999; pp 271-283.

Table of Contents Graphic



# Table of Contents Graphic



